Attached files
file | filename |
---|---|
10-K - FORM 10-K - CHEMED CORP | l38929e10vk.htm |
EX-21 - EX-21 - CHEMED CORP | l38929exv21.htm |
EX-24 - EX-24 - CHEMED CORP | l38929exv24.htm |
EX-23 - EX-23 - CHEMED CORP | l38929exv23.htm |
EX-12 - EX-12 - CHEMED CORP | l38929exv12.htm |
EX-31.2 - EX-31.2 - CHEMED CORP | l38929exv31w2.htm |
EX-31.3 - EX-31.3 - CHEMED CORP | l38929exv31w3.htm |
EX-31.1 - EX-31.1 - CHEMED CORP | l38929exv31w1.htm |
EX-32.3 - EX-32.3 - CHEMED CORP | l38929exv32w3.htm |
EX-32.1 - EX-32.1 - CHEMED CORP | l38929exv32w1.htm |
EX-32.2 - EX-32.2 - CHEMED CORP | l38929exv32w2.htm |
Exhibit 13
Chemed Corporation and Subsidiary Companies
Financial Review
Contents
Report of Independent Registered Public Accounting Firm |
2 | |||
Consolidated Statement of Income |
3 | |||
Consolidated Balance Sheet |
4 | |||
Consolidated Statement of Cash Flows |
5 | |||
Consolidated Statement of Changes in Stockholders Equity |
6 | |||
Notes to Consolidated Financial Statements |
7 | |||
Unaudited Summary of Quarterly Results |
32 | |||
Selected Financial Data |
34 | |||
Unaudited Consolidating Statements of Income |
35 | |||
Managements Discussion and Analysis of Financial Conditions and
Results of Operations |
38 | |||
Officers and Directors Listing and Corporate Information |
IBC |
MANAGEMENTS REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING
The Companys management is responsible for establishing and maintaining adequate internal
control over financial reporting, as that term is defined in Exchange Act Rules 13a-15(f) and
15d-15(f). A companys internal control over financial reporting is a process designed to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting
principles. A companys internal control over financial reporting includes those policies and
procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately
and fairly reflect the transactions and disposition of the assets of the company; (ii) provide
reasonable assurance that transactions are recorded as necessary to permit preparation of financial
statements in accordance with generally accepted accounting principles, and that receipts and
expenditures of the company are being made only in accordance with authorization of management and
directors of the company; and (iii) provide reasonable assurance regarding prevention or timely
detection of unauthorized acquisition, use, or disposition of the Companys assets that could have
a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent
or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are
subject to the risk that controls may become inadequate because of changes in conditions, or that
the degree of compliance with the policies or procedures may deteriorate.
The Companys management, including the President and Chief Executive Officer, Executive Vice
President and Chief Financial Officer and Vice President and Controller, has conducted an
evaluation of the effectiveness of its internal control over financial reporting as of December 31,
2009, based on the framework established in Internal ControlIntegrated Framework issued by the
Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on this
evaluation, management concluded that internal control over financial reporting was effective as of
December 31, 2009, based on criteria in Internal ControlIntegrated Framework issued by COSO.
PricewaterhouseCoopers LLP, our independent registered public accounting firm, has audited the
effectiveness of the Companys internal control over financial reporting as of December 31, 2009,
as stated in their report which appears on page 2.
1
Chemed Corporation and Subsidiary Companies
Report of Independent Registered Public Accounting Firm
To the Board of Directors and Stockholders of Chemed Corporation
In our
opinion, the accompanying consolidated balance sheet and the related consolidated statements
of income, stockholders equity and cash flows present fairly, in all material respects, the
financial position of Chemed Corporation and its subsidiaries at December 31, 2009 and 2008, and
the results of their operations and their cash flows for each of the three years in the period
ended December 31, 2009 in conformity with accounting principles generally accepted in the United
States of America. Also in our opinion, the Company maintained, in all material respects,
effective internal control over financial reporting as of December 31, 2009, based on criteria
established in Internal Control Integrated Framework issued by the Committee of Sponsoring
Organizations of the Treadway Commission (COSO). The Companys management is responsible for these
financial statements, for maintaining effective internal control over financial reporting and for
its assessment of the effectiveness of internal control over financial reporting, included in the
accompanying Managements Report on Internal Control over Financial Reporting. Our responsibility
is to express opinions on these financial statements and on the Companys internal control over
financial reporting based on our integrated audits. We conducted our audits in accordance with the
standards of the Public Company Accounting Oversight Board (United States). Those standards
require that we plan and perform the audits to obtain reasonable assurance about whether the
financial statements are free of material misstatement and whether effective internal control over
financial reporting was maintained in all material respects. Our audits of the financial
statements included examining, on a test basis, evidence supporting the amounts and disclosures in
the financial statements, assessing the accounting principles used and significant estimates made
by management, and evaluating the overall financial statement presentation. Our audit of internal
control over financial reporting included obtaining an understanding of internal control over
financial reporting, assessing the risk that a material weakness exists, and testing and evaluating
the design and operating effectiveness of internal control based on the assessed risk. Our audits
also included performing such other procedures as we considered necessary in the circumstances. We
believe that our audits provide a reasonable basis for our opinions.
As discussed in Note 2 to the consolidated financial statements, the Company changed the manner in
which it accounts for convertible debt instruments that may be settled in cash upon conversion,
including partial cash settlement, effective January 1, 2009.
A companys internal control over financial reporting is a process designed to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally accepted accounting principles. A
companys internal control over financial reporting includes those policies and procedures that
(i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect
the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance
that transactions are recorded as necessary to permit preparation of financial statements in
accordance with generally accepted accounting principles, and that receipts and expenditures of the
company are being made only in accordance with authorizations of management and directors of the
company; and (iii) provide reasonable assurance regarding prevention or timely detection of
unauthorized acquisition, use, or disposition of the companys assets that could have a material
effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or
detect misstatements. Also, projections of any evaluation of effectiveness to future periods are
subject to the risk that controls may become inadequate because of changes in conditions, or that
the degree of compliance with the policies or procedures may deteriorate.
/s/ PricewaterhouseCoopers LLP
|
||
Cincinnati, Ohio |
||
February 26, 2010 |
2
Chemed Corporation and Subsidiary Companies
CONSOLIDATED STATEMENT OF INCOME
Chemed Corporation and Subsidiary Companies
(in thousands, except per share data)
(in thousands, except per share data)
For the Years Ended December 31, | 2009 | 2008 | 2007 | |||||||||
Continuing Operations |
||||||||||||
Service revenues and sales |
$ | 1,190,236 | $ | 1,148,941 | $ | 1,100,058 | ||||||
Cost of services provided and goods sold
(excluding depreciation) |
834,574 | 810,547 | 767,066 | |||||||||
Selling, general and administrative expenses |
197,426 | 175,333 | 184,060 | |||||||||
Depreciation |
21,535 | 21,581 | 20,118 | |||||||||
Amortization |
6,367 | 5,924 | 5,270 | |||||||||
Other operating expensesnet (Note 6) |
3,989 | 2,699 | 789 | |||||||||
Total costs and expenses |
1,063,891 | 1,016,084 | 977,303 | |||||||||
Income from operations |
126,345 | 132,857 | 122,755 | |||||||||
Interest expense |
(11,599 | ) | (12,123 | ) | (14,921 | ) | ||||||
Gain/(loss) on extinguishment of debt (Note 2) |
| 3,406 | (13,798 | ) | ||||||||
Other income/(expense)net (Note 10) |
5,874 | (8,736 | ) | 4,125 | ||||||||
Income before income taxes |
120,620 | 115,404 | 98,161 | |||||||||
Income taxes (Note 11) |
(46,583 | ) | (47,035 | ) | (37,721 | ) | ||||||
Income from continuing operations |
74,037 | 68,369 | 60,440 | |||||||||
Discontinued Operations, Net of Income Taxes (Note
8) |
(253 | ) | (1,088 | ) | 1,201 | |||||||
Net Income |
$ | 73,784 | $ | 67,281 | $ | 61,641 | ||||||
Earnings Per Share (Note 15) |
||||||||||||
Income from continuing operations |
$ | 3.30 | $ | 2.97 | $ | 2.46 | ||||||
Net Income |
$ | 3.29 | $ | 2.92 | $ | 2.51 | ||||||
Diluted Earnings Per Share (Note 15) |
||||||||||||
Income from continuing operations |
$ | 3.26 | $ | 2.93 | $ | 2.41 | ||||||
Net Income |
$ | 3.24 | $ | 2.88 | $ | 2.46 | ||||||
Average Number of Shares Outstanding (Note 15) |
||||||||||||
Earnings per share |
22,451 | 23,058 | 24,520 | |||||||||
Diluted earnings per share |
22,742 | 23,374 | 25,077 | |||||||||
The Notes to Consolidated Financial Statements are integral parts of this statement.
3
Chemed Corporation and Subsidiary Companies
CONSOLIDATED BALANCE SHEET
Chemed Corporation and Subsidiary Companies
(in thousands, except shares and per share data)
(in thousands, except shares and per share data)
December 31, | 2009 | 2008 | ||||||
Assets |
||||||||
Current assets |
||||||||
Cash and cash equivalents (Note 9) |
$ | 112,416 | $ | 3,628 | ||||
Accounts receivable less allowances of $12,595 (2008 - $10,320) |
53,461 | 98,076 | ||||||
Inventories |
7,543 | 7,569 | ||||||
Current deferred income taxes (Note 11) |
13,701 | 15,392 | ||||||
Prepaid expenses |
11,137 | 11,268 | ||||||
Total current assets |
198,258 | 135,933 | ||||||
Investments of deferred compensation plans held in trust (Notes 14
and 16) |
24,158 | 22,628 | ||||||
Properties and equipment, at cost, less accumulated depreciation
(Note 12) |
75,358 | 76,962 | ||||||
Identifiable intangible assets less accumulated amortization of
$25,349 (2008 - $21,272) (Note 5) |
57,920 | 61,303 | ||||||
Goodwill (Note 5) |
450,042 | 448,721 | ||||||
Other assets |
13,734 | 14,075 | ||||||
Total Assets |
$ | 819,470 | $ | 759,622 | ||||
Liabilities |
||||||||
Current liabilities |
||||||||
Accounts payable |
$ | 52,071 | $ | 52,810 | ||||
Current portion of long-term debt (Note 2) |
| 10,169 | ||||||
Income taxes (Note 11) |
63 | 2,181 | ||||||
Accrued insurance |
35,161 | 35,994 | ||||||
Accrued compensation |
34,662 | 40,741 | ||||||
Other current liabilities |
14,127 | 12,180 | ||||||
Total current liabilities |
136,084 | 154,075 | ||||||
Deferred income taxes (Note 11) |
25,924 | 22,477 | ||||||
Long-term debt (Note 2) |
152,127 | 158,210 | ||||||
Deferred compensation liabilities (Note 14) |
23,637 | 22,417 | ||||||
Other liabilities |
4,536 | 5,612 | ||||||
Commitments and contingencies (Notes 13, 18 and 19) |
||||||||
Total Liabilities |
342,308 | 362,791 | ||||||
Stockholders Equity |
||||||||
Capital stock authorized 80,000,000 shares $1 par; issued
29,890,628 shares
(2008 - 29,514,877 shares) |
29,891 | 29,515 | ||||||
Paid-in capital |
335,890 | 313,516 | ||||||
Retained earnings |
403,366 | 337,739 | ||||||
Treasury stock - 7,275,070 shares (2008 - 7,100,475 shares), at cost |
(293,941 | ) | (285,977 | ) | ||||
Deferred compensation payable in Company stock (Note 14) |
1,956 | 2,038 | ||||||
Total Stockholders Equity |
477,162 | 396,831 | ||||||
Total Liabilities and Stockholders Equity |
$ | 819,470 | $ | 759,622 | ||||
The Notes to Consolidated Financial Statements are integral parts of this statement.
4
Chemed Corporation and Subsidiary Companies
CONSOLIDATED STATEMENT OF CASH FLOWS
Chemed Corporation and Subsidiary Companies
(in thousands)
(in thousands)
For the Years Ended December 31, | 2009 | 2008 | 2007 | |||||||||
Cash Flows from Operating Activities |
||||||||||||
Net income |
$ | 73,784 | $ | 67,281 | $ | 61,641 | ||||||
Adjustments to reconcile net income to net cash provided
by operations: |
||||||||||||
Depreciation and amortization |
27,902 | 27,505 | 25,388 | |||||||||
Provision for uncollectible accounts receivable |
10,833 | 9,820 | 8,373 | |||||||||
Stock option expense |
8,639 | 7,303 | 4,665 | |||||||||
Amortization of discount on covertible notes |
6,617 | 6,560 | 3,940 | |||||||||
Provision for deferred income taxes (Note 11) |
4,979 | (2,772 | ) | 6,771 | ||||||||
Noncash portion of long-term incentive compensation |
4,385 | | 6,154 | |||||||||
Amortization of debt issuance costs |
632 | 618 | 923 | |||||||||
Discontinued operations (Note 8) |
253 | 1,088 | (1,201 | ) | ||||||||
Noncash loss/(gain) on early extinguishment of debt |
| (3,406 | ) | 7,235 | ||||||||
Loss on impairment of equipment |
| 2,699 | | |||||||||
Changes in operating assets and liabilities, excluding
amounts acquired in business combinations: |
||||||||||||
Decrease/(increase) in accounts receivable |
33,754 | (6,659 | ) | (18,299 | ) | |||||||
Decrease/(increase) in inventories |
29 | (898 | ) | (18 | ) | |||||||
Decrease/(increase) in prepaid expenses |
(455 | ) | 305 | (549 | ) | |||||||
Increase/(decrease) in accounts payable
and other current liabilities |
(8,109 | ) | 5,585 | (8,416 | ) | |||||||
Increase/(decrease) in income taxes |
623 | (776 | ) | 6,321 | ||||||||
Decrease/(increase) in other assets |
(1,678 | ) | 5,480 | (3,655 | ) | |||||||
Increase/(decrease) in other liabilities |
272 | (6,423 | ) | 4,426 | ||||||||
Excess tax benefit on share-based compensation |
(1,955 | ) | (2,422 | ) | (3,091 | ) | ||||||
Other sources/(uses) |
327 | 1,195 | (1,024 | ) | ||||||||
Net cash provided by operating activities |
160,832 | 112,083 | 99,584 | |||||||||
Cash Flows from Investing Activities |
||||||||||||
Capital expenditures |
(21,496 | ) | (26,094 | ) | (26,640 | ) | ||||||
Business combinations, net of cash acquired (Note 7) |
(1,919 | ) | (11,200 | ) | (1,079 | ) | ||||||
Proceeds from sales of property and equipment |
1,577 | 387 | 3,104 | |||||||||
Net proceeds/(uses) of discontinued operations (Note 8) |
(630 | ) | 8,824 | (5,402 | ) | |||||||
Other uses |
(374 | ) | (544 | ) | (1,701 | ) | ||||||
Net cash used by investing activities |
(22,842 | ) | (28,627 | ) | (31,718 | ) | ||||||
Cash Flows from Financing Activities |
||||||||||||
Repayment of long-term debt (Note 2) |
(14,669 | ) | (18,713 | ) | (225,709 | ) | ||||||
Net change in revolving line of credit |
(8,200 | ) | 8,200 | | ||||||||
Dividends paid |
(8,157 | ) | (5,543 | ) | (5,888 | ) | ||||||
Purchases of treasury stock (Note 21) |
(4,225 | ) | (69,788 | ) | (131,704 | ) | ||||||
Increase/(decrease) in cash overdraft payable |
2,891 | (856 | ) | (919 | ) | |||||||
Excess tax benefit on share-based compensation |
1,955 | 2,422 | 3,091 | |||||||||
Proceeds from exercise of stock options (Note 3) |
545 | 291 | 2,467 | |||||||||
Proceeds from issuance of long-term debt (Note 2) |
| | 245,106 | |||||||||
Purchase of note hedges (Note 2) |
| | (55,100 | ) | ||||||||
Proceeds from conversion feature of debt, net of costs
(Note 2) |
| | 53,206 | |||||||||
Proceeds from issuance of warrants (Note 2) |
| | 27,614 | |||||||||
Debt issuance costs |
| | (5,261 | ) | ||||||||
Other sources/(uses) |
658 | (829 | ) | 945 | ||||||||
Net cash used by financing activities |
(29,202 | ) | (84,816 | ) | (92,152 | ) | ||||||
Increase/(decrease) in cash and cash equivalents |
108,788 | (1,360 | ) | (24,286 | ) | |||||||
Cash and cash equivalents at beginning of year |
3,628 | 4,988 | 29,274 | |||||||||
Cash and cash equivalents at end of year |
$ | 112,416 | $ | 3,628 | $ | 4,988 | ||||||
The Notes to Consolidated Financial Statements are integral parts of this statement.
5
Chemed Corporation and Subsidiary Companies
CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS EQUITY
Chemed Corporation and Subsidiary Companies
(in thousands, except per share data)
(in thousands, except per share data)
Deferred | ||||||||||||||||||||||||
Compensation | ||||||||||||||||||||||||
Treasury | Payable in | |||||||||||||||||||||||
Capital | Paid-in | Retained | Stock- | Company | ||||||||||||||||||||
Stock | Capital | Earnings | at Cost | Stock | Total | |||||||||||||||||||
Balance at December 31, 2006 |
$ | 28,850 | $ | 252,639 | $ | 215,517 | $ | (78,064 | ) | $ | 2,419 | $ | 421,361 | |||||||||||
Cumulative
effect of change in accounting principle as of January 1, 2007 (Notes 1 and 11) |
| | 4,731 | | | 4,731 | ||||||||||||||||||
Net income |
| | 61,641 | | | 61,641 | ||||||||||||||||||
Dividends paid ($.24 per share) |
| | (5,888 | ) | | | (5,888 | ) | ||||||||||||||||
Stock awards and exercise of stock options (Note 3) |
411 | 21,141 | | (7,032 | ) | | 14,520 | |||||||||||||||||
Purchases of treasury stock (Note 21) |
| | | (127,881 | ) | | (127,881 | ) | ||||||||||||||||
Purchase of note hedges (Note 2) |
| (55,100 | ) | | | | (55,100 | ) | ||||||||||||||||
Proceeds from conversion feature of debt, net of costs (Note 2) |
| 53,206 | | | | 53,206 | ||||||||||||||||||
Proceeds from issuance of warrants (Note 2) |
| 27,614 | | | | 27,614 | ||||||||||||||||||
Other |
| 1,598 | | (64 | ) | 62 | 1,596 | |||||||||||||||||
Balance at December 31, 2007 |
29,261 | 301,098 | 276,001 | (213,041 | ) | 2,481 | 395,800 | |||||||||||||||||
Net income |
| | 67,281 | | | 67,281 | ||||||||||||||||||
Dividends paid ($.24 per share) |
| | (5,543 | ) | | | (5,543 | ) | ||||||||||||||||
Stock awards and exercise of stock options (Note 3) |
254 | 15,752 | | (6,253 | ) | | 9,753 | |||||||||||||||||
Purchases of treasury stock (Note 21) |
| | | (67,125 | ) | | (67,125 | ) | ||||||||||||||||
Repurchase of conversion feature of notes |
| (2,117 | ) | | | | (2,117 | ) | ||||||||||||||||
Other |
| (1,217 | ) | | 442 | (443 | ) | (1,218 | ) | |||||||||||||||
Balance at December 31, 2008 |
29,515 | 313,516 | 337,739 | (285,977 | ) | 2,038 | 396,831 | |||||||||||||||||
Net income |
| | 73,784 | | | 73,784 | ||||||||||||||||||
Dividends paid ($.36 per share) |
| | (8,157 | ) | | | (8,157 | ) | ||||||||||||||||
Stock awards and exercise of stock options (Note 3) |
376 | 21,741 | | (7,305 | ) | | 14,812 | |||||||||||||||||
Purchases of treasury stock (Note 21) |
| | | (742 | ) | | (742 | ) | ||||||||||||||||
Other |
| 633 | | 83 | (82 | ) | 634 | |||||||||||||||||
Balance at December 31, 2009 |
$ | 29,891 | $ | 335,890 | $ | 403,366 | $ | (293,941 | ) | $ | 1,956 | $ | 477,162 | |||||||||||
The Notes to Consolidated Financial Statements are integral parts of this statement.
6
Chemed Corporation and Subsidiary Companies
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Chemed Corporation and Subsidiary Companies
Chemed Corporation and Subsidiary Companies
1. | Summary of Significant Accounting Policies |
NATURE OF OPERATIONS
We operate through our two wholly owned subsidiaries: VITAS Healthcare Corporation
(VITAS) and Roto-Rooter Group, Inc. (Roto-Rooter). VITAS focuses on hospice care that helps
make terminally ill patients final days as comfortable as possible. Through its team of
doctors, nurses, home health aides, social workers, clergy and volunteers, VITAS provides direct
medical services to patients, as well as spiritual and emotional counseling to both patients and
their families. Roto-Rooter is focused on providing plumbing and drain cleaning services to both
residential and commercial customers. Through its network of company-owned branches, independent
contractors and franchisees, Roto-Rooter offers plumbing and drain cleaning service to over 90%
of the U.S. population.
PRINCIPLES OF CONSOLIDATION
The consolidated financial statements include the accounts of Chemed Corporation and its
wholly owned subsidiaries. All significant intercompany transactions have been eliminated.
We have analyzed the provisions of the Financial Accounting Standards Board (FASB)
authoritative guidance on the consolidation of variable interest entities relative to our
contractual relationships with Roto-Rooters independent contractors and franchisees. The
guidance requires the primary beneficiary of a Variable Interest Entity (VIE) to consolidate
the accounts of the VIE. Based upon the guidance provided by the FASB, we have concluded that
certain of the independent contractors may be VIEs. We believe consolidation, if required, of
the accounts of any independent contractor for which we might be the primary beneficiary would
not materially impact our financial position, results of operations or cash flow. The
franchisees are not VIEs.
CASH EQUIVALENTS
Cash equivalents comprise short-term, highly liquid investments, including money market
funds, that have original maturities of three months or less.
ACCOUNTS AND LOANS RECEIVABLE AND CONCENTRATION OF RISK
Accounts and loans receivable are recorded at the principal balance outstanding less
estimated allowances for uncollectible accounts. For the Roto-Rooter segment, allowances for
trade accounts receivable are generally provided for accounts more than 90 days past due,
although collection efforts continue beyond that time. Due to the small number of loans
receivable outstanding, allowances for loan losses are determined on a case-by-case basis. For
the VITAS segment, allowances for accounts receivable are provided on accounts based on expected
collection rates by payer types. The expected collection rate is based on both historical
averages and known current trends. Final write-off of overdue accounts or loans receivable is
made when all reasonable collection efforts have been made and payment is not forthcoming. We
closely monitor our receivables and periodically review procedures for granting credit to
attempt to hold losses to a minimum.
As of December 31, 2009 and 2008, approximately 43% and 68%, respectively, of VITAS total
accounts receivable balance were due from Medicare and 39% and 23%, respectively, of VITAS
total accounts receivable balance were due from various state Medicaid programs. Combined
accounts receivable from Medicare and Medicaid represent 76% of the net accounts receivable in
the accompanying consolidated balance sheet as of December 31, 2009.
As of December 31, 2009, VITAS has approximately $9.9 million in unbilled revenue included
in accounts receivable (December 31, 2008 $13.9 million). The unbilled revenue at VITAS
relates to hospice programs currently undergoing focused medical reviews (FMR). During FMR,
surveyors working on behalf of the U.S. Federal government review certain patient files for
compliance with Medicare regulations. During the time the patient file is under review, we are
unable to bill for care provided to those patients. We make appropriate provisions to reduce
our accounts receivable balance for any governmental or other payer reviews resulting in denials
of patient service revenue. We believe our hospice programs comply with all payer requirements
at the time of billing. However, we cannot predict whether future billing reviews or similar
audits by payers will result in material denials or reductions in revenue.
INVENTORIES
Substantially all of the inventories are either general merchandise or finished goods.
Inventories are stated at the lower of cost or market. For determining the value of
inventories, cost methods that reasonably approximate the first-in, first-out (FIFO) method
are used.
7
Chemed Corporation and Subsidiary Companies
DEPRECIATION AND PROPERTIES AND EQUIPMENT
Depreciation of properties and equipment is computed using the straight-line method over
the estimated useful lives of the assets. Leasehold improvements are amortized over the lesser
of the remaining lease terms (excluding option terms) or their useful lives. Expenditures for
maintenance, repairs, renewals and betterments that do not materially prolong the useful lives
of the assets are expensed as incurred. The cost of property retired or sold and the related
accumulated depreciation are removed from the accounts, and the resulting gain or loss is
reflected currently in income.
Expenditures for major software purchases and software developed for internal use are
capitalized and depreciated using the straight-line method over the estimated useful lives of
the assets. For software developed for internal use, external direct costs for materials and
services and certain internal payroll and related fringe benefit costs are capitalized in
accordance with the FASBs authoritative guidance on accounting for the costs of computer
software developed or obtained for internal use.
The weighted average lives of our property and equipment at December 31, 2009, were:
Buildings |
11.9 | yrs. | ||
Transportation equipment |
15.6 | |||
Machinery and equipment |
5.6 | |||
Computer software |
4.0 | |||
Furniture and fixtures |
4.8 |
GOODWILL AND INTANGIBLE ASSETS
Identifiable, definite-lived intangible assets arise from purchase business combinations
and are amortized using either an accelerated method or the straight-line method over the
estimated useful lives of the assets. The selection of an amortization method is based on which
method best reflects the economic pattern of usage of the asset. The VITAS trade name is
considered to have an indefinite life. Goodwill and the VITAS trade name are tested at least
annually for impairment.
The weighted average lives of our identifiable, definite-lived intangible assets at
December 31, 2009, were:
Covenants not to compete |
6.4 | yrs. | ||
Reacquired franchise rights |
7.8 | |||
Referral networks |
10.0 | |||
Customer lists |
13.3 |
LONG-LIVED ASSETS
If we believe a triggering event may have occurred that indicates a possible impairment of
our long-lived assets, we perform an estimate and valuation of the future benefits of our
long-lived assets (other than goodwill and the VITAS trade name) based on key financial
indicators. If the projected undiscounted cash flows of a major business unit indicate that
property and equipment or identifiable, definite-lived intangible assets have been impaired, a
write-down to fair value is made.
OTHER ASSETS
Debt issuance costs are included in other assets and are amortized using the effective
interest method over the life of the debt.
We capitalize the direct costs of obtaining licenses to operate either hospice programs or
plumbing operations subject to a minimum capitalization threshold. These costs are amortized
over the life of the license using the straight-line method. Certain licenses are granted
without an expiration and thus, we believe them to be indefinite-lived assets subject to
impairment testing on at least an annual basis.
REVENUE RECOGNITION
Both the VITAS segment and Roto-Rooter segment recognize service revenues and sales when
the earnings process has been completed. Generally, this occurs when services are provided or
products are delivered. Sales of Roto-Rooter products, including drain cleaning machines and
drain cleaning solution, comprise less than 3% of our total service revenues and sales for each
of the three years in the period ended December 31, 2009.
8
Chemed Corporation and Subsidiary Companies
VITAS recognizes revenue at the estimated realizable amount due from third-party payers,
which are primarily Medicare and Medicaid. Payers may deny payment for services in whole or in
part on the basis that such services are not eligible for coverage and do not qualify for
reimbursement. We estimate denials each period and make adequate provision in the financial
statements. The estimate of denials is based on historical trends and known circumstances and
does not vary materially from period to period on an aggregate basis. Medicare billings are
subject to certain limitations, as described below.
VITAS is subject to certain limitations on Medicare payments for services. Specifically,
if the number of inpatient care days any hospice program provides to Medicare beneficiaries
exceeds 20% of the total days of hospice care such program provided to all Medicare patients for
an annual period beginning September 28, the days in excess of the 20% figure may be reimbursed
only at the routine homecare rate. None of VITAS hospice programs exceeded the payment limits
on inpatient services in 2009, 2008 or 2007.
VITAS is also subject to a Medicare annual per-beneficiary cap (Medicare cap).
Compliance with the Medicare cap is measured by comparing the total Medicare payments received
under a Medicare provider number with respect to services provided to all Medicare hospice care
beneficiaries in the program or programs covered by that Medicare provider number between
November 1 of each year and October 31 of the following year with the product of the
per-beneficiary cap amount and the number of Medicare beneficiaries electing hospice care for
the first time from that hospice program or programs from September 28 through September 27 of
the following year.
We actively monitor each of our hospice programs, by provider number, as to their specific
admission, discharge rate and median length of stay data in an attempt to determine whether
revenues are likely to exceed the annual per-beneficiary Medicare cap. Should we determine that
revenues for a program are likely to exceed the Medicare cap based on projected trends, we
attempt to institute corrective actions, which include changes to the patient mix and increased
patient admissions. However, should we project our corrective action will not prevent that
program from exceeding its Medicare cap, we estimate the amount of revenue recognized during the
period that will require repayment to the Federal government under the Medicare cap and record
the amount as a reduction to service revenue.
Our estimate of the Medicare cap liability is particularly sensitive to allocations made by
our fiscal intermediary relative to patient transfers between hospices. We are allocated a
percentage of the Medicare cap based on the days a patient spent in our care as compared to the
total days a patient spent in all hospice care. The allocation for patient transfers cannot be
determined until a patient dies. As the number of days a patient spends in hospice is based on
a future event, this allocation process may take several years. Therefore, we use only
first-time Medicare admissions in our estimate of the Medicare cap billing limitation. This
method assumes that credit received for patients who transfer into our program will be offset by
credit lost from patients who transfer out of our program. The amount we record is our best
estimate of the liability as of the date of the financial statements but could change as more
patient information becomes available.
During the years ended December 31, 2009, 2008 and 2007, we recorded pretax charges in
continuing operations of $1.6 million, $235,000 and $242,000, respectively, for the estimated
Medicare cap liability. The amount recorded in 2009 relates to two programs projected
liability through year end for the 2010 measurement period. The majority of the liability
relates to one program which is VITAS largest hospice program. We are currently pursuing the
corrective actions mentioned above to attempt to mitigate the liability before the end of the
measurement period. The amount recorded in 2008 relates to one programs liability through year
end for the 2009 measurement period. This amount was subsequently reversed during the 2009
fiscal year due to improved admission trends. The amount recorded in 2007 relates primarily to
retroactive billings for prior-measurement periods due to patients who transferred between
multiple hospice providers. The components of the pretax charge in 2009 are as follows (in
thousands):
2010 Measurement period |
$ | 1,783 | ||
2009 Measurement period |
(235 | ) | ||
2008 Measurement period |
| |||
Retroactive billings |
95 | |||
Total |
$ | 1,643 | ||
The U.S. government revises hospice reimbursement rates on an annual basis using the
Hospice Wage Index (HWI) and the Consumer Price Index plus a phase out of the Budget Neutrality
Adjustment Factor (BNAF). The HWI is geographically adjusted to reflect local differences in
wages. The BNAF is a portion of inflation calculated in prior years that is being eliminated or
phased out over a seven year period. In August 2008, the U.S. government announced
9
Chemed Corporation and Subsidiary Companies
a 25% reduction in the BNAF for its fiscal 2009 (October 2008 through September 2009)
pursuant to a three year phase-out of the BNAF. The February 2009 American Recovery and
Reinvestment Act mandated a one year delay in the BNAF phase-out. In August 2009, the Centers
for Medicare and Medicaid Services (CMS) revised the phase-out schedule of the BNAF. CMS
reduced the increase in hospice reimbursement by 10% of the BNAF effective October 1, 2009.
The remaining 90% of the BNAF will be phased out over the next six years by revising the October
1 reimbursement adjustment by 15% of the original BNAF inflation factor. Based upon this
revised schedule, 100% of the BNAF will be eliminated on October 1, 2015. As a result, included
in the twelve months ended December 31, 2009, is $1.95 million of revenue for the retroactive
price increase related to services provided by VITAS in the fourth quarter of 2008.
CHARITY CARE
VITAS provides charity care, in certain circumstances, to patients without charge when
management of the hospice program determines that the patient does not have the financial
wherewithal to make payment. There is no revenue or associated accounts receivable in the
accompanying consolidated financial statements related to charity care.
Using the applicable Medicare billing rate for the respective levels of care, charity care
provided during the years ended December 31, 2009, 2008 and 2007 was $8.6 million, $9.2 million
and $9.9 million, respectively.
SALES TAX
The Roto-Rooter segment collects sales tax from customers when required by state and
federal laws. We record the amount of sales tax collected net in the accompanying consolidated
statement of income.
GUARANTEES
In the normal course of business, Roto-Rooter enters into various guarantees and
indemnifications in our relationships with customers and others. These arrangements include
guarantees of services for periods ranging from one day to one year and product satisfaction
guarantees. Mainly due to our technicians being commission-based, guarantees and
indemnifications do not materially impact our financial condition, results of operations or cash
flows. Therefore, no liability for guarantees has been recorded as of December 31, 2009 or
2008.
OPERATING EXPENSES
Cost of services provided and goods sold (excluding depreciation) includes salaries, wages
and benefits of service providers and field personnel, material costs, medical supplies and
equipment, pharmaceuticals, insurance costs, service vehicle costs and other expenses directly
related to providing service revenues or generating sales. Selling, general and administrative
expenses include salaries, wages, stock option expense and benefits of selling, marketing and
administrative employees, advertising expenses, communications and branch telephone expenses,
office rent and operating costs, legal, banking and professional fees and other administrative
costs. The cost associated with VITAS sales personnel is included in cost of services provided
and goods sold (excluding depreciation).
ADVERTISING
We expense the production costs of advertising the first time the advertising takes place.
The costs of telephone directory listings are expensed when the directories are placed in
circulation. These directories are generally in circulation for approximately one year, at
which point they are typically replaced by the publisher with a new directory. We generally pay
for directory placement assuming it is in circulation for one year. If the directory is in
circulation for less than or greater than one year, we receive a credit or additional billing,
as necessary. We do not control the timing of when a new directory is placed in circulation.
Advertising expense in continuing operations for the year ended December 31, 2009, was $27.0
million (2008 $26.8 million; 2007 $26.0 million).
COMPUTATION OF EARNINGS PER SHARE
Earnings per share are computed using the weighted average number of shares of capital
stock outstanding. Diluted earnings per share reflect the dilutive impact of our outstanding
stock options and nonvested stock awards. Stock options whose exercise price is greater than
the average market price of our stock are excluded from the computation of diluted earnings per
share.
STOCK-BASED COMPENSATION PLANS
Stock-based compensation cost is measured at the grant date, based on the fair value of the
award and recognized as expense over the employees requisite service period on a straight-line
basis.
10
Chemed Corporation and Subsidiary Companies
INSURANCE ACCRUALS
For our Roto-Rooter segment and Corporate Office, we self-insure for all casualty insurance
claims (workers compensation, auto liability and general liability). As a result, we closely
monitor and frequently evaluate our historical claims experience to estimate the appropriate
level of accrual for self-insured claims. Our third-party administrator (TPA) processes and
reviews claims on a monthly basis. Currently, our exposure on any single claim is capped at
$500,000. In developing our estimates, we accumulate historical claims data for the previous 10
years to calculate loss development factors (LDF) by insurance coverage type. LDFs are
applied to known claims to estimate the ultimate potential liability for known and unknown
claims for each open policy year. LDFs are updated annually. Because this methodology relies
heavily on historical claims data, the key risk is whether the historical claims are an accurate
predictor of future claims exposure. The risk also exists that certain claims have been
incurred and not reported on a timely basis. To mitigate these risks, in conjunction with our
TPA, we closely monitor claims to ensure timely accumulation of data and compare claims trends
with the industry experience of our TPA.
For the VITAS segment, we self-insure for workers compensation claims. Currently, VITAS
exposure on any single claim is capped at $750,000. For VITAS self-insurance accruals for
workers compensation, the valuation methods used are similar to those used internally for our
other business units.
Our casualty insurance liabilities are recorded gross before any estimated recovery for
amounts exceeding our stop loss limits. Estimated recoveries from insurance carriers are
recorded as accounts receivable.
TAXES ON INCOME
Deferred taxes are provided on an asset and liability method whereby deferred tax assets
are recognized for deductible temporary differences and operating loss carry-forwards and
deferred tax liabilities are recognized for taxable temporary differences. Temporary
differences are the differences between the reported amount of assets and liabilities and their
tax basis. Deferred tax assets are reduced by a valuation allowance when, in our opinion, it is
more likely than not that some portion or all of the deferred tax assets will not be realized.
Deferred tax assets and liabilities are adjusted for the effects of changes in laws and rates on
the date of enactment.
We are subject to income taxes in Canada, U.S. Federal and most state jurisdictions.
Significant judgment is required to determine our provision for income taxes. Our financial
statements reflect expected future tax consequences of such uncertain positions assuming the
taxing authorities full knowledge of the position and all relevant facts.
ESTIMATES
The preparation of consolidated financial statements in conformity with accounting
principles generally accepted in the United States requires us to make estimates and assumptions
that affect amounts reported in the consolidated financial statements and accompanying notes.
Actual results could differ from those estimates. Disclosures of aftertax expenses and
adjustments are based on estimates of the effective income tax rates for the applicable
segments.
RECENT ACCOUNTING STATEMENTS
In June 2009, the FASB issued additional guidance related to the consolidation of VIEs,
which makes significant changes to the model for determining who should consolidate an entity
and also addresses how often this assessment should be performed. The determination of who
should consolidate a VIE will be based on both quantitative and qualitative factors relating to
control, as well as risks and benefits of ownership. This guidance is effective in 2010 for
calendar-year companies and is to be adopted through a cumulative-effect adjustment. Based on
our analysis, we believe that neither Roto-Rooters independent contractors nor franchisees
qualify as VIEs under the new guidance.
2. | Long-Term Debt and Lines of Credit |
A summary of our long-term debt follows (in thousands):
December 31, | ||||||||
2009 | 2008 | |||||||
Convertible Notes due 2014 |
$ | 152,127 | $ | 145,510 | ||||
Term loan due 2007-2012 |
| 14,500 | ||||||
Revolving line of credit |
| 8,200 | ||||||
Other |
| 169 | ||||||
Subtotal |
152,127 | 168,379 | ||||||
Less current portion |
| (10,169 | ) | |||||
Long-term debt, less
current portion |
$ | 152,127 | $ | 158,210 | ||||
11
Chemed Corporation and Subsidiary Companies
In May 2008, the FASB issued authoritative guidance for accounting for convertible
debt instruments that may be settled in cash upon conversion including partial cash settlement.
This guidance requires all convertible debentures classified as Instruments B or C, as defined,
to separately account for the debt and equity pieces of the instrument. Convertible debentures
classified as Instruments B may be settled in either stock or cash equivalent to the conversion
value and convertible debentures classified as Instruments C must settle the accreted value of
the obligation in cash and may satisfy the excess conversion value in either cash or stock. At
inception of the convertible instrument, cash flows related to the convertible instrument are to
be discounted using a market rate of interest. We adopted the provisions of the guidance on
January 1, 2009 and applied the guidance retrospectively. Upon adoption, the Notes had a
discount of approximately $55.1 million. For 2008 and 2007
interest expense increased and retained earnings decreased $6.1
million and $3.7 million, respectively ($4.0 million and $2.3 million respectively, net of
income taxes).
The increase in interest expense results in a reduction in EPS and
diluted EPS of $0.20 and $0.09 in 2008 and 2007, respectively.
The following amounts are included in our consolidated balance sheet related to the
Notes (in thousands):
December 31, | ||||||||
2009 | 2008 | |||||||
Principal amount of convertible debentures |
$ | 186,956 | $ | 186,956 | ||||
Unamortized debt discount |
(34,829 | ) | (41,446 | ) | ||||
Carrying amount of convertible debentures |
$ | 152,127 | $ | 145,510 | ||||
Additional paid in capital (net of tax) |
$ | 31,310 | $ | 31,310 | ||||
The following amounts comprise interest expense included in our consolidated income
statement (in thousands):
December 31, | ||||||||||||
2009 | 2008 | 2007 | ||||||||||
Cash interest expense |
$ | 4,350 | $ | 4,945 | $ | 10,058 | ||||||
Non-cash amortization of debt discount |
6,617 | 6,560 | 3,940 | |||||||||
Amortization of debt costs |
632 | 618 | 923 | |||||||||
Total interest expense |
$ | 11,599 | $ | 12,123 | $ | 14,921 | ||||||
The unamortized debt discount will be amortized using the effective interest method
over the remaining life of the Notes. The effective rate on the Notes after adoption of the
standard is 6.875%.
The average interest rate for our long-term debt was 1.9% and 2.1% for the years ended
December 31, 2009 and 2008, respectively.
In the fourth quarter of 2008, we purchased approximately $13.0 million face value of our
Convertible Notes due 2014 for approximately $8.5 million. This resulted in a pre-tax net gain
of $3.4 million comprised of $3.7 million related to the purchase of the Convertible Notes
partially offset by $300,000 in the write-off of unamortized debt issuance costs. The net gain
was recorded as a gain on extinguishment of debt in the accompanying statement of income in
2008.
2007 REFINANCING
On May 2, 2007, we entered into a new senior secured credit facility with JPMorgan Chase
Bank (the 2007 Facility) to replace our existing credit facility. The 2007 Facility includes
a $100 million term loan, a $175 million revolving credit facility and a $100 million expansion
feature. The facility has a 5-year maturity with principal payments on the term loan due
quarterly and on the revolving credit facility due at maturity. Interest is payable quarterly
at a floating rate equal to our choice of various indices plus a specified margin based on our
leverage ratio. The interest rate at the inception of the agreement was LIBOR plus 0.875%. In
connection with replacing the existing credit facility, we wrote-off approximately $2.3 million
in deferred debt costs. This write-off was recorded as loss on extinguishment of debt in the
accompanying statement of income in 2007.
On May 4, 2007, we used the proceeds from the 2007 Facility to fund the redemption of our
$150 million 8.75% Senior Notes due 2011. The redemption was made pursuant to the terms of the
indenture at a price of 104.375% plus accrued but unpaid interest. In connection with the
redemption, we wrote-off approximately $4.8 million in deferred debt costs. The premium payment
of $6.6 million and the write-off of deferred debt costs was recorded as loss on extinguishment
of debt in the accompanying statement of income in 2007.
12
Chemed Corporation and Subsidiary Companies
On May 8, 2007, we entered into a Purchase Agreement with J.P. Morgan Securities Inc. and
Citigroup Global Markets Inc. (the Initial Purchasers) for issuance and sale of $180 million
in aggregate principal amount of our 1.875% Senior Convertible Notes due 2014 (the Notes). On
May 9, 2007, the Initial Purchasers exercised an over-allotment option to purchase an additional
$20 million in aggregate principal amount of Notes. On May 14, 2007, a total of $200 million in
aggregate principal amount of the Notes were sold to the Initial Purchasers at a price of $1,000
per Note, less an underwriting fee of $27.50 per Note.
We received approximately $194 million in net proceeds from the sale of the Notes after
paying underwriting fees, legal and other expenses. Proceeds from the offering were used to
purchase treasury shares of our stock, as discussed in Note 21 and to pay down a portion of the
2007 Facility. We pay interest on the Notes on May 15 and November 15 of each year, beginning
on November 15, 2007. The Notes mature on May 15, 2014. The Notes are guaranteed on an unsecured
senior basis by each of our subsidiaries that are a borrower or a guarantor under any senior
credit facility, as defined in the Indenture. The Notes are convertible, under certain
circumstances, into our Capital Stock at an initial conversion rate of 12.3874 shares per $1,000
principal amount of Notes. This conversion rate is equivalent to an initial conversion price of
approximately $80.73 per share. Prior to March 1, 2014, holders may convert their Notes under
certain circumstances. On and after March 1, 2014, the Notes will be convertible at any time
prior to the close of business three days prior to the stated maturity date of the Notes. Upon
conversion of a Note, if the conversion value is $1,000 or less, holders will receive cash equal
to the lesser of $1,000 or the conversion value of the number of shares of our Capital Stock. If
the conversion value exceeds $1,000, in addition to this, holders will receive shares of our
Capital Stock for the excess amount. The Indenture contains customary terms and covenants that
upon certain events of default, including without limitation, failure to pay when due any
principal amount, a fundamental change or certain cross defaults in other agreements or
instruments, occurring and continuing; either the trustee or the holders of 25% in aggregate
principal amount of the Notes may declare the principal of the Notes and any accrued and unpaid
interest through the date of such declaration immediately due and payable. In the case of
certain events of bankruptcy or insolvency relating to any significant subsidiary or to us, the
principal amount of the Notes and accrued interest automatically becomes due and payable.
The conversion rate on the Notes is adjusted upon certain corporate events including a
quarterly dividend payment in excess of $0.06 per share. In August 2009 and November 2009, we
declared quarterly dividends of $0.12 per share. This has the effect of changing the
conversion rate to 12.4213 ($80.51 per share) at December 31, 2009.
Pursuant to the FASBs guidance on accounting for derivative instruments indexed to, and
potentially settled in a companys own stock as well as the guidance on the meaning of indexed
to a companys own stock, the Notes are accounted for as convertible debt in the accompanying
consolidated balance sheet and the embedded options within the Notes have not been accounted for
as separate derivatives. On August 17, 2007, we filed a shelf registration statement, that
became immediately effective, to register the Notes and Capital Stock issuable upon conversion.
On May 8, 2007, we entered into a purchased call transaction and a warrant transaction
(written call) with JPMorgan Chase, National Association and Citibank, N.A. (the
Counterparties). The purchased call options cover approximately 2,477,000 shares of our
Capital Stock, which under most circumstances represents the maximum number of shares of Capital
Stock that underlie the Notes. Concurrently with entering into the purchased call options, we
entered into warrant transactions with each of the Counterparties. Pursuant to the warrant
transactions, we sold to the Counterparties warrants to purchase in the aggregate approximately
2,477,000 shares of our Capital Stock. In most cases, the sold warrants may not be exercised
prior to the maturity of the Notes.
The purchased call options and sold warrants are separate contracts with the
Counterparties, are not part of the terms of the Notes and do not affect the rights of holders
under the Notes. A holder of the Notes will not have any rights with respect to the purchased
call options or the sold warrants. The purchased call options are expected to reduce the
potential dilution upon conversion of the Notes if the market value per share of the Capital
Stock at the time of exercise is greater than the conversion price of the Notes at time of
exercise. The sold warrants have an exercise price of $105.44 and are expected to result in some
dilution should the price of our Capital Stock exceed this exercise price.
Our net cost for these transactions was approximately $27.3 million. Pursuant to FASBs
authoritative guidance, the purchased call option and the sold warrants are accounted for as
equity transactions. Therefore, our net cost was recorded as a decrease in stockholders equity
in the accompanying consolidated balance sheet.
Since May 2007, we have repaid the $100 million term note under the 2007 Facility using
cash on hand. The only required long-term debt payment ($152.1 million) is for the Convertible
Notes due in 2014.
13
Chemed Corporation and Subsidiary Companies
During 2009, 2008 and 2007, interest totaling $258,000, $659,000 and $951,000,
respectively, was capitalized. Summarized below are the total amounts of interest paid during
the years ended December 31 (in thousands):
2009 |
$ | 4,667 | ||
2008 |
5,628 | |||
2007 |
15,466 |
DEBT COVENANTS
Collectively, the 2007 Facility and the Notes require us to meet certain restrictive
financial covenants, in addition to non-financial covenants, including maximum leverage ratios,
minimum fixed charge coverage and consolidated net worth ratios, limits on operating leases and
minimum asset value limits. We are in compliance with all debt covenants, financial and
non-financial, as of December 31, 2009. We have issued $28.8 million in standby letters of
credit as of December 31, 2009, mainly for insurance purposes. Issued letters of credit reduce
our available credit under the revolving credit agreement. As of December 31, 2009, we have
approximately $146.2 million of unused lines of credit available and eligible to be drawn down
under our revolving credit facility, excluding the expansion feature.
3. | Stock-Based Compensation Plans |
We provide employees the opportunity to acquire our stock through a number of plans, as
follows:
| We have five stock incentive plans under which 6,700,000 shares can be issued to key employees through a grant of stock awards and/or options to purchase shares. The Compensation/Incentive Committee (CIC) of the Board of Directors administers these plans. All options granted under these plans provide for a purchase price equal to the market value of the stock at the date of grant. The latest plan, covering a total of 3,000,000 shares, was adopted in May 2006 and amended in August 2006. The plans are not qualified, restricted or incentive plans under the U.S. Internal Revenue Code. The terms of each plan differ slightly; however, stock options issued under the plans generally have a maximum term of 10 years. Under one plan, adopted in 1999, up to 500,000 shares may be issued to employees who are not our officers or directors. | ||
| In May 2002, our shareholders approved the adoption of the Executive Long-Term Incentive Plan (LTIP) covering our officers and key employees. The CIC periodically approves a pool of shares to be awarded based on stock price hurdles, EBITDA targets and a discretionary component for the LTIP. | ||
In May 2009, the CIC approved a new stock-price target portion of the Companys LTIP. The new stock price hurdles are as follows: |
Stock | Shares to | |||||||
Price | be | |||||||
Hurdle | Issued | |||||||
$ | 54.00 | 22,500 | ||||||
$ | 58.00 | 33,750 | ||||||
$ | 62.00 | 33,750 | ||||||
Total | 90,000 | |||||||
The stock price hurdles must be achieved during 30 trading days out of any 60 trading day period during the three years ending February 28, 2012. | |||
In October 2009, we met the cumulative EBITDA target established in 2007 and on November 10, 2009 the CIC approved a stock grant of 96,200 shares and the related allocation to participants. The pretax cost of the stock grant was $5.0 million and is included in selling, general and administrative expenses in the accompanying consolidated statement of income. | |||
In November 2009, the CIC approved a pool of shares to be awarded based on new EBITDA targets. The participants of the LTIP may be awarded 80,000 shares of capital stock if we attain Adjusted EBITDA of either $640 million for the three-year period beginning January 1, 2010, or $825 million for the four-year period beginning January 1, 2010. The CIC also established a discretionary pool of 37,000 shares of capital stock. | |||
There were no share-based awards made from the LTIP in fiscal 2008. |
14
Chemed Corporation and Subsidiary Companies
| We maintain an Employee Stock Purchase Plan (ESPP). The ESPP allows eligible participants to purchase our shares through payroll deductions at current market value. We pay administrative and broker fees associated with the ESPP. Shares purchased for the ESPP are purchased on the open market and credited directly to participants accounts. In accordance with the FASBs guidance, the ESPP is non-compensatory. |
For the years ended December 31, 2009, 2008 and 2007, we recorded $2.3 million, $1.9
million and $1.2 million, respectively, in amortization expense in the accompanying statement of
income for stock-based compensation related to the amortization of restricted stock awards
granted. For the years ended December 31, 2009, 2008 and 2007, we recorded $8.6 million, $7.3
million and $4.7 million, respectively, in selling, general and administrative expenses for
stock-based compensation related to stock options granted. There were no capitalized
stock-based compensation costs for any period presented.
As of December 31, 2009, approximately $3.9 million of total unrecognized compensation
costs related to non-vested stock awards are expected to be recognized over a weighted average
period of 1.9 years. As of December 31, 2009, approximately $8.9 million of total unrecognized
compensation costs related to non-vested stock options are expected to be recognized over a
weighted average period of 1.7 years.
The following table summarizes stock option and award activity:
Stock Awards | ||||||||||||||||
Stock Options | Weighted | |||||||||||||||
Weighted | Average | |||||||||||||||
Number | Average | Number | Grant- | |||||||||||||
of | Exercise | of | Date | |||||||||||||
Shares | Price | Shares | Price | |||||||||||||
Stock-based compensation shares: |
||||||||||||||||
Outstanding at January 1, 2009 |
2,175,159 | $ | 40.99 | 137,216 | $ | 46.80 | ||||||||||
Granted |
508,600 | 44.02 | 160,199 | 44.54 | ||||||||||||
Exercised/Vested |
(216,732 | ) | 20.47 | (126,260 | ) | 42.72 | ||||||||||
Canceled/Forfeited |
(14,800 | ) | 52.89 | (1,180 | ) | 21.78 | ||||||||||
Outstanding at December 31,
2009 |
2,452,227 | $ | 43.36 | 169,975 | $ | 47.87 | ||||||||||
Vested at December 31, 2009 |
1,458,866 | $ | 42.75 | |||||||||||||
The weighted average contractual life of outstanding and exercisable options was 6.0
years at December 31, 2009.
Options outstanding at December 31, 2009, were in the following exercise price ranges:
Weighted | ||||||||||||
Number | Average | Aggregate | ||||||||||
of | Exercise | Intrinsic | ||||||||||
Exercise Price Range | Options | Price | Value | |||||||||
$16.10 to $27.18 |
362,742 | $ | 20.23 | $ | 10,062,000 | |||||||
$27.19 to $40.78 |
763,268 | $ | 35.12 | $ | 9,808,000 | |||||||
$40.79 to $70.00 |
1,326,217 | $ | 54.43 | $ | |
The total intrinsic value of stock options exercised during the years ended December
31, 2009, 2008 and 2007 was $5.1 million, $5.2 million and $7.8 million, respectively. The
total intrinsic value of stock options that were vested as of December 31, 2009, 2008 and 2007
was $15.5 million, $11.3 million and $33.5 million, respectively. The total intrinsic value of
stock awards vested during the years ended December 31, 2009, 2008 and 2007 was $5.6 million,
$3.4 million and $8.0 million, respectively. The total cash received from employees as a result
of employee stock option exercises for the years ended December 31, 2009, 2008 and 2007 was
$545,000, $291,000 and $2.5 million, respectively. In connection with these exercises, the
excess tax benefits realized for the years ended December 31, 2009, 2008 and 2007, were $2.0
million, $2.4 million and $3.1 million, respectively. We settle employee stock options with
newly issued shares.
15
Chemed Corporation and Subsidiary Companies
We estimate the fair value of stock options using the Black-Scholes valuation model,
consistent with the provisions of the FASBs and the Securities and Exchange Commissions
(SEC) guidance. We determine expected term, volatility, dividend yield and forfeiture rate
based on our historical experience. We believe that historical experience is the best indicator
of these factors. For purposes of determining the key assumptions and the related fair value of
the options granted, we analyzed the participants of the LTIP separately from the other stock
option recipients. The assumptions we used to value the 2009, 2008 and 2007 grants are as
follows:
2009 | 2008 | 2007 | ||||||||||||||||||||||
LTIP | LTIP | LTIP | ||||||||||||||||||||||
Participants | All Others | Participants | All Others | Participants | All Others | |||||||||||||||||||
Stock price on date of issuance |
$ | 44.02 | $ | 44.02 | $ | 33.75 | $ | 33.75 | $ | 67.96 | $ | 67.96 | ||||||||||||
Grant date fair value per share |
$ | 14.95 | $ | 12.49 | $ | 11.18 | $ | 10.18 | $ | 25.18 | $ | 21.87 | ||||||||||||
Number of options granted |
320,000 | 188,600 | 325,000 | 183,600 | 320,000 | 150,600 | ||||||||||||||||||
Expected term (years) |
5.7 | 4.1 | 5.7 | 4.3 | 5.8 | 4.3 | ||||||||||||||||||
Risk free rate of return |
1.91 | % | 1.44 | % | 3.08 | % | 2.92 | % | 4.74 | % | 4.76 | % | ||||||||||||
Volatility |
35.0 | % | 35.0 | % | 31.8 | % | 34.0 | % | 30.4 | % | 31.3 | % | ||||||||||||
Dividend yield |
0.6 | % | 0.6 | % | 0.7 | % | 0.7 | % | 0.4 | % | 0.4 | % | ||||||||||||
Forfeiture rate |
| 5.5 | % | | 5.20 | % | | 5.20 | % |
4. | Segments and Nature of the Business |
Our segments include the VITAS segment and the Roto-Rooter segment. Relative contributions
of each segment to service revenues and sales were 72% and 28%, respectively, in 2009 and 69%
and 31%, respectively, in 2008. The vast majority of our service revenues and sales from
continuing operations are generated from business within the United States.
The reportable segments have been defined along service lines, which is consistent with the
way the businesses are managed. In determining reportable segments, the Roto-Rooter Services and
Roto-Rooter Franchising and Products operating units of the Roto-Rooter segment have been
aggregated on the basis of possessing similar operating and economic characteristics. The
characteristics of these operating segments and the basis for aggregation are reviewed annually.
Accordingly, the reportable segments are defined as follows:
| The VITAS segment provides hospice services for patients with severe, life-limiting illnesses. This type of care is aimed at making the terminally ill patients end of life as comfortable and pain-free as possible. Hospice care is typically available to patients who have been initially certified or re-certified as terminally ill (i.e., a prognosis of six months or less) by their attending physician, if any, and the hospice physician. VITAS offers all levels of hospice care in a given market, including routine home care, inpatient care and continuous care. Over 90% of VITAS revenues are derived through the Medicare and Medicaid reimbursement programs. | ||
| The Roto-Rooter segment provides repair and maintenance services to residential and commercial accounts using the Roto-Rooter registered service marks. Such services include plumbing and sewer, drain and pipe cleaning. They are delivered through company-owned and operated territories, independent contractor-operated territories and franchised locations. This segment also manufactures and sells products and equipment used to provide such services. | ||
| We report corporate administrative expenses and unallocated investing and financing income and expense not directly related to either segment as Corporate. Corporate administrative expense includes the stewardship, accounting and reporting, legal, tax and other costs of operating a publicly held corporation. Corporate investing and financing income and expenses include the costs and income associated with corporate debt and investment arrangements. Beginning on January 1, 2008, the income statement impact of our deferred compensation plans covering Roto-Rooter employees has been classified as a Corporate activity. Historically, the income statement impact has been recorded as a Roto-Rooter activity. Due to the volatility in the capital markets, Roto-Rooters operational results were being distorted in our management reporting as a result of the activity of the deferred compensation plans. Our Chief Operating Decision Maker (CODM), determined that the income statement impact of Roto-Rooters deferred compensation plans is more appropriately classified as a Corporate activity. Our internal management reporting documents have been changed to reflect this determination. The table below has been reclassified to conform all periods presented. |
16
Chemed Corporation and Subsidiary Companies
Segment data for our continuing operations are set forth below (in thousands):
For the Years Ended December 31, | ||||||||||||
2009 | 2008 | 2007 | ||||||||||
Revenues by Type of Service |
||||||||||||
VITAS |
||||||||||||
Routine homecare |
$ | 615,408 | $ | 585,891 | $ | 546,872 | ||||||
Continuous care |
141,272 | 124,894 | 115,801 | |||||||||
General inpatient |
97,356 | 97,895 | 92,995 | |||||||||
Estimated BNAF |
1,950 | | | |||||||||
Medicare cap |
(1,643 | ) | (235 | ) | (242 | ) | ||||||
Total segment |
854,343 | 808,445 | 755,426 | |||||||||
Roto-Rooter |
||||||||||||
Sewer and drain cleaning |
136,503 | 146,150 | 151,111 | |||||||||
Plumbing repair and maintenance |
151,072 | 145,831 | 143,021 | |||||||||
Independent contractors |
21,620 | 21,968 | 22,070 | |||||||||
HVAC repair and maintenance |
4,031 | 4,059 | 3,929 | |||||||||
Other products and services |
22,667 | 22,488 | 24,501 | |||||||||
Total segment |
335,893 | 340,496 | 344,632 | |||||||||
Total service revenues and sales |
$ | 1,190,236 | $ | 1,148,941 | $ | 1,100,058 | ||||||
Aftertax Segment Earnings/(Loss) |
||||||||||||
VITAS |
$ | 72,157 | $ | 64,719 | $ | 59,833 | ||||||
Roto-Rooter |
33,246 | 33,592 | 38,971 | |||||||||
Total |
105,403 | 98,311 | 98,804 | |||||||||
Corporate |
(31,366 | ) | (29,942 | ) | (38,364 | ) | ||||||
Discontinued operations |
(253 | ) | (1,088 | ) | 1,201 | |||||||
Net income |
$ | 73,784 | $ | 67,281 | $ | 61,641 | ||||||
Interest Income |
||||||||||||
VITAS |
$ | 4,582 | $ | 5,336 | $ | 7,405 | ||||||
Roto-Rooter |
2,587 | 3,824 | 5,370 | |||||||||
Total |
7,169 | 9,160 | 12,775 | |||||||||
Corporate |
83 | 489 | 2,776 | |||||||||
Intercompany eliminations |
(6,829 | ) | (8,907 | ) | (12,247 | ) | ||||||
Total interest income |
$ | 423 | $ | 742 | $ | 3,304 | ||||||
Interest Expense |
||||||||||||
VITAS |
$ | 374 | $ | 155 | $ | 146 | ||||||
Roto-Rooter |
186 | 246 | 495 | |||||||||
Total |
560 | 401 | 641 | |||||||||
Corporate |
11,039 | 11,722 | 14,280 | |||||||||
Total interest expense |
$ | 11,599 | $ | 12,123 | $ | 14,921 | ||||||
Income Tax Provision |
||||||||||||
VITAS |
$ | 43,921 | $ | 38,710 | $ | 35,722 | ||||||
Roto-Rooter |
20,493 | 20,742 | 24,145 | |||||||||
Total |
64,414 | 59,452 | 59,867 | |||||||||
Corporate |
(17,831 | ) | (12,417 | ) | (22,146 | ) | ||||||
Total income tax provision |
$ | 46,583 | $ | 47,035 | $ | 37,721 | ||||||
17
Chemed Corporation and Subsidiary Companies
For the Years Ended December 31, | ||||||||||||
2009 | 2008 | 2007 | ||||||||||
Identifiable Assets |
||||||||||||
VITAS |
$ | 476,621 | $ | 523,178 | $ | 527,809 | ||||||
Roto-Rooter |
191,254 | 188,003 | 185,982 | |||||||||
Total |
667,875 | 711,181 | 713,791 | |||||||||
Corporate |
151,595 | 48,441 | 55,154 | |||||||||
Total identifiable assets |
$ | 819,470 | $ | 759,622 | $ | 768,945 | ||||||
Additions to Long-Lived Assets |
||||||||||||
VITAS |
$ | 14,913 | $ | 8,797 | $ | 20,435 | ||||||
Roto-Rooter |
8,067 | 18,906 | 9,341 | |||||||||
Total |
22,980 | 27,703 | 29,776 | |||||||||
Corporate |
448 | 9,492 | 193 | |||||||||
Total additions to
long-lived assets |
$ | 23,428 | $ | 37,195 | $ | 29,969 | ||||||
Depreciation and Amortization |
||||||||||||
VITAS |
$ | 17,228 | $ | 16,984 | $ | 15,430 | ||||||
Roto-Rooter |
8,182 | 8,344 | 8,419 | |||||||||
Total |
25,410 | 25,328 | 23,849 | |||||||||
Corporate |
2,492 | 2,177 | 1,539 | |||||||||
Total depreciation and
amortization |
$ | 27,902 | $ | 27,505 | $ | 25,388 | ||||||
5. | Goodwill and Intangible Assets |
Amortization of definite-lived intangible assets from continuing operations was $4.0
million for each of the years ended December 31, 2009, 2008 and 2007, respectively. The
following is a schedule by year of projected amortization expense for definite-lived intangible
assets (in thousands):
2010 |
$ | 2,091 | ||
2011 |
1,292 | |||
2012 |
1,289 | |||
2013 |
1,289 | |||
2014 |
328 | |||
Thereafter |
272 |
The balance in identifiable intangible assets comprises the following (in thousands):
Gross | Accumulated | Net Book | ||||||||||
Asset | Amortization | Value | ||||||||||
December 31, 2009 |
||||||||||||
Referral networks |
$ | 21,200 | $ | (16,240 | ) | $ | 4,960 | |||||
Covenants not to compete |
9,092 | (8,006 | ) | 1,086 | ||||||||
Customer lists |
1,227 | (1,060 | ) | 167 | ||||||||
Reacquired franchise Rights |
450 | (43 | ) | 407 | ||||||||
Subtotal definite-lived intangibles |
31,969 | (25,349 | ) | 6,620 | ||||||||
VITAS trade name |
51,300 | | 51,300 | |||||||||
Total |
$ | 83,269 | $ | (25,349 | ) | $ | 57,920 | |||||
December 31, 2008 |
||||||||||||
Referral networks |
$ | 21,140 | $ | (13,445 | ) | $ | 7,695 | |||||
Covenants not to compete |
8,911 | (6,813 | ) | 2,098 | ||||||||
Customer lists |
1,223 | (1,013 | ) | 210 | ||||||||
Subtotal definite-lived intangibles |
31,274 | (21,271 | ) | 10,003 | ||||||||
VITAS trade name |
51,300 | | 51,300 | |||||||||
Total |
$ | 82,574 | $ | (21,271 | ) | $ | 61,303 | |||||
18
Chemed Corporation and Subsidiary Companies
The date of our annual goodwill and indefinite-lived intangible asset impairment
analysis is October 1. For all reporting units included in continuing operations, the
impairment tests indicated that the fair value of our goodwill exceeds its carrying amount.
Our goodwill and VITAS trade name are not impaired.
We consider that Roto-Rooter Co. (RRC), Roto-Rooter Services Co. (RRSC) and VITAS are
appropriate reporting units. We consider RRC and RRSC as separate reporting units but one
operating segment. This is appropriate as they each have their own set of general ledger
accounts that can be analyzed at one level below an operating segment per the definition of a
reporting unit in FASB guidance.
We used two methods to estimate the business enterprise value of each reporting unit (a)
a comparison to key enterprise value ratios of publicly traded market competitors and (b) an
allocation of total Chemed market value at October 1, 2009 to each reporting unit. The final
estimate of the business enterprise value of each reporting unit was determined using a simple
average of the two methods.
For valuing the VITAS tradename, we performed a discounted cash flow analysis on the
expected theoretical royalty cash stream from the VITAS tradename.
6. | Other Operating Expenses Net |
Other expenses from continuing operations include the following pretax charges (in
thousands):
For the Year Ended December 31, | ||||||||||||
2009 | 2008 | 2007 | ||||||||||
Costs related to a contested proxy solicitation |
$ | 3,989 | $ | | $ | | ||||||
Impairment of long-lived assets |
| 2,699 | | |||||||||
Cost related to class action litigation |
| | 1,927 | |||||||||
Gain on sale of property |
| | (1,138 | ) | ||||||||
Total other expenses |
$ | 3,989 | $ | 2,699 | $ | 789 | ||||||
For the twelve-month period ended December 31, 2009, we recorded pretax expenses of
$4.0 million related to the costs of a contested proxy solicitation.
In December 2008, the Executive Committee of the Board of Directors authorized us to place
a 29 year-old, eight passenger Hawker jet for sale. We
determined that this asset met the
definition of held for sale under the FASBs guidance on, accounting for the impairment or
disposal of long-lived assets. As a result, we discontinued
depreciation on the jet and
wrote-down the asset to its fair value less selling costs resulting in a pre-tax charge to
other operating expenses net of approximately
$2.7 million. In March 2009, we sold the jet
and recognized a $112,000 gain on disposal.
7. | Business Combinations |
During 2009, we completed two business combinations within the Roto-Rooter segment for $1.9
million in cash to increase our market penetration in Detroit, Michigan and Grand Rapids,
Michigan. We made no acquisitions within the VITAS segment during 2009. The purchase price of
these acquisitions was allocated as follows (in thousands):
Working capital |
$ | (13 | ) | |
Identifiable intangible assets |
690 | |||
Goodwill |
1,067 | |||
Other assets and liabilities net |
175 | |||
$ | 1,919 | |||
During 2008, we completed four business combinations within the Roto-Rooter segment
for $11.2 million in cash to increase our market penetration in Colorado Springs, Colorado;
Dayton, Ohio; Eugene, Oregon; and Topeka, Kansas. We made no acquisitions within the VITAS
segment during 2008.
During 2007, we completed one business combination within the Roto-Rooter segment for $1.1
million in cash to increase our market penetration in Burlington, Vermont. We made no
acquisitions within the VITAS segment during 2007.
19
Chemed Corporation and Subsidiary Companies
The unaudited pro forma results of operations, assuming purchase business combinations
completed in 2009 and 2008 were completed on January 1, 2008, and do not materially impact the
accompanying consolidated financial statements. The results of operations of each of the above
business combinations are included in our results of operations from the date of the respective
acquisition. The allocations of purchase price are immaterial to the accompanying consolidated
financial statements.
8. | Discontinued Operations |
Discontinued operations comprise (in thousands, except per share amounts):
For the Years Ended December 31, | ||||||||||||
2009 | 2008 | 2007 | ||||||||||
Phoenix (2006): |
||||||||||||
Income/(loss) before income taxes |
$ | | $ | | $ | 1,938 | ||||||
Income taxes |
| | (737 | ) | ||||||||
Income/(loss) from operations, net of income taxes |
| | 1,201 | |||||||||
Adjustment to accruals of operations discontinued in prior years: |
||||||||||||
Casualty insurance costs |
(400 | ) | (1,719 | ) | | |||||||
Loss before income taxes |
(400 | ) | (1,719 | ) | | |||||||
All other income taxes |
147 | 631 | | |||||||||
Total adjustments |
(253 | ) | (1,088 | ) | | |||||||
Total discontinued operations |
$ | (253 | ) | $ | (1,088 | ) | $ | 1,201 | ||||
Earnings/(loss) per share |
$ | (0.01 | ) | $ | (0.05 | ) | $ | 0.05 | ||||
Diluted earnings/(loss) per share |
$ | (0.02 | ) | $ | (0.05 | ) | $ | 0.05 | ||||
In December 2009 and 2008, we recorded a $400,000 and $1.7 million pre-tax charge,
respectively, for residual casualty insurance claims related to our discontinued operations.
In September 2006, our Board of Directors approved and we announced our intention to exit
the hospice market in Phoenix, Arizona. In October 2007, we received notification from the
Federal governments fiscal intermediary regarding our Medicare cap liabilities related to the
2006 measurement period. The notification revealed that we were over accrued at our
discontinued Phoenix operation by $1.9 million. We recorded the reversal of this over accrual
and its related tax effects in discontinued operations during the year ended December 31, 2007.
As of December 31, 2009, we have $198,000 accrued for potential retroactive billings related to
the Medicare Cap for Phoenix.
At December 31, 2009 and 2008, the accrual for our estimated liability for potential
environmental cleanup and related costs arising from the sale of DuBois amounted to $1.7
million. Of the 2009 balance, $826,000 is included in other current liabilities and $901,000 is
included in other liabilities (long-term). We are contingently liable for additional
DuBois-related environmental cleanup and related costs up to a maximum of $14.9 million. On the
basis of a continuing evaluation of the potential liability, we believe it is not probable this
additional liability will be paid. Accordingly, no provision for this contingent liability has
been recorded. The potential liability is not insured, and the recorded liability does not
assume the recovery of insurance proceeds. Also, the environmental liability has not been
discounted because it is not possible to reliably project the timing of payments. We believe
that any adjustments to our recorded liability will not materially adversely affect our
financial position, results of operations or cash flows.
Revenues generated by discontinued operations were $1.9 million for the year ended December
31, 2007. There were no revenues generated by discontinued operations for the years ended
December 31, 2009 and 2008.
At December 31, 2009, other current liabilities include accruals of $1.0 million and other
liabilities (long-term) include accruals of $1.2 million for costs related to discontinued
operations. The estimated timing of payments of these liabilities follows (in thousands):
2010 |
$ | 1,043 | ||
2011 |
300 | |||
Thereafter |
832 | |||
$ | 2,175 | |||
20
Chemed Corporation and Subsidiary Companies
9. | Cash Overdrafts and Cash Equivalents |
Included in accounts payable are cash overdrafts of $11.7 million and $8.8 million as of
December 31, 2009 and 2008, respectively.
From time to time throughout the year, we invest excess cash in money market funds or
repurchase agreements directly with major commercial banks. We do not physically hold the
collateral for repurchase agreements, but the term is less than 10 days. We closely monitor the
creditworthiness of the institutions with which we invest our overnight funds and the quality of
the collateral underlying those investments. We had $109.3 million in cash equivalents as of
December 31, 2009. There were no cash equivalents as of December 31, 2008. The weighted
average rate of return for our cash equivalents was 0.3% in 2009 and 2.3% in 2008.
10. | Other Income/ (Expense) Net |
Other income/ (expense)net from continuing operations comprises the following (in thousands):
For the Years Ended December31, | ||||||||||||
2009 | 2008 | 2007 | ||||||||||
Market value gains/(losses) on assets held in
deferred compensation trust |
$ | 5,802 | $ | (9,140 | ) | $ | 963 | |||||
(Loss)/gain on disposal of property and
equipment |
(369 | ) | (415 | ) | (286 | ) | ||||||
Interest Income |
423 | 742 | 3,304 | |||||||||
Other net |
18 | 77 | 144 | |||||||||
Total other income |
$ | 5,874 | $ | (8,736 | ) | $ | 4,125 | |||||
The offset for market value gains or losses on assets held in deferred compensation trust
is recorded in selling, general and administrative expenses.
11. | Income Taxes |
The provision for income taxes comprises the following (in thousands):
For the Years Ended December 31, | ||||||||||||
2009 | 2008 | 2007 | ||||||||||
Continuing Operations: |
||||||||||||
Current |
||||||||||||
U.S. federal |
$ | 36,182 | $ | 42,914 | $ | 26,458 | ||||||
U.S. state and local |
4,960 | 6,226 | 3,995 | |||||||||
Foreign |
462 | 667 | 497 | |||||||||
Deferred |
||||||||||||
U.S. federal, state and local |
4,980 | (2,710 | ) | 6,715 | ||||||||
Foreign |
(1 | ) | (62 | ) | 56 | |||||||
Total |
$ | 46,583 | $ | 47,035 | $ | 37,721 | ||||||
Discontinued Operations: |
||||||||||||
Current U.S. federal |
$ | (65 | ) | $ | (735 | ) | $ | 647 | ||||
Current U.S. state and local |
(5 | ) | (55 | ) | 90 | |||||||
Deferred U.S. federal, state and local |
(77 | ) | 159 | | ||||||||
Total |
$ | (147 | ) | $ | (631 | ) | $ | 737 | ||||
21
Chemed Corporation and Subsidiary Companies
A summary of the temporary differences that give rise to deferred tax assets/
(liabilities) follows (in thousands):
2009 | 2008 | |||||||
Accrued liabilities |
$ | 23,609 | $ | 25,094 | ||||
Stock compensation expense |
7,991 | 4,825 | ||||||
Allowance for uncollectible accounts receivable |
1,862 | 1,839 | ||||||
State net operating loss carryforwards |
1,439 | 1,567 | ||||||
Other |
2,420 | 3,245 | ||||||
Deferred income tax assets |
37,321 | 36,570 | ||||||
Amortization of intangible assets |
(37,975 | ) | (35,791 | ) | ||||
Accelerated tax depreciation |
(9,495 | ) | (6,325 | ) | ||||
Currents assets |
(1,179 | ) | (1,103 | ) | ||||
Other |
(623 | ) | (172 | ) | ||||
Deferred income tax liabilities |
(49,272 | ) | (43,391 | ) | ||||
Net deferred income tax liabilities |
$ | ( 11,951 | ) | $ | (6,821 | ) | ||
Included in other assets at December 31, 2009, are deferred income tax assets of
$272,000 (2008 $264,000). At December 31, 2009 and 2008, state net operating loss
carryforwards were $26.6 million and $28.5 million, respectively. These net operating losses
will expire, in varying amounts, between 2010 and 2029. Based on our history of operating
earnings, we have determined that our operating income will, more likely than not, be sufficient
to ensure realization of our deferred income tax assets.
The cumulative effect upon adoption of FASBs guidance on accounting for uncertain income
taxes was to reduce our accrual for uncertain tax positions by approximately $4.7 million, which
has been recorded in retained earnings as of January 1, 2007, in the accompanying financial
statements. After adoption, we had approximately $1.3 million in unrecognized tax benefits.
The majority of this amount would affect our effective tax rate, if recognized in a future
period. The years ended December 31, 2006, and forward remain open for review for Federal
income tax purposes. The earliest open year relating to any of our material state jurisdictions
is the fiscal year ended December 31, 2004. During the next twelve months, we do not anticipate
a material net change in unrecognized tax benefits.
As permitted by this guidance, we classify interest related to our accrual for uncertain
tax positions in separate interest accounts. As of December 31, 2009 and 2008, we have
approximately $149,000 and $152,000, respectively, accrued in interest payable related to
uncertain tax positions. These accruals are included in other current liabilities in the
accompanying consolidated balance sheet. Net interest expense related to uncertain tax
positions included in interest expense in the accompanying consolidated statement of income is
not material.
A roll forward of the significant changes to our unrecognized tax benefits is as follows
(in thousands):
2009 | 2008 | 2007 | ||||||||||
Balance at January 1, |
$ | 1,202 | $ | 1,169 | $ | 1,281 | ||||||
Unrecognized tax benefits due to positions taken in current year |
136 | 413 | 178 | |||||||||
Gross change due to positions taken in prior years |
| 53 | | |||||||||
Decrease due to settlement with taxing authorities |
(214 | ) | (174 | ) | (40 | ) | ||||||
Decrease due to expiration of statute of limitations |
(93 | ) | (259 | ) | (250 | ) | ||||||
Other |
(21 | ) | | | ||||||||
Balance at December 31, |
$ | 1,010 | $ | 1,202 | $ | 1,169 | ||||||
22
Chemed Corporation and Subsidiary Companies
The difference between the actual income tax provision for continuing operations and
the income tax provision calculated at the statutory U.S. federal tax rate is explained as
follows (in thousands):
2009 | 2008 | 2007 | ||||||||||
Income tax provision calculated using
the statutory rate of 35% |
$ | 42,217 | $ | 40,391 | $ | 34,356 | ||||||
State and local income taxes,
less federal income tax effect |
3,837 | 3,928 | 3,265 | |||||||||
Impact of deferred compensation plans |
(190 | ) | 3,084 | (186 | ) | |||||||
Tax accrual adjustments |
(111 | ) | 107 | (87 | ) | |||||||
Other net |
830 | (475 | ) | 373 | ||||||||
Income tax provision |
$ | 46,583 | $ | 47,035 | $ | 37,721 | ||||||
Effective tax rate |
38.6 | % | 40.8 | % | 38.4 | % | ||||||
Summarized below are the total amounts of income taxes paid during the years ended
December 31 (in thousands):
2009 |
$ | 40,872 | ||
2008 |
50,535 | |||
2007 |
24,345 |
Provision has not been made for additional taxes on $35.1 million of undistributed
earnings of our domestic subsidiaries. Should we elect to sell our interest in all of these
businesses rather than to effect a tax-free liquidation, additional taxes amounting to
approximately $12.9 million would be incurred based on current income tax rates.
12. | Properties and Equipment |
A summary of properties and equipment follows (in thousands):
December 31, | ||||||||
2009 | 2008 | |||||||
Land |
$ | 1,360 | $ | 1,355 | ||||
Buildings |
29,699 | 28,150 | ||||||
Transportation equipment |
17,318 | 19,329 | ||||||
Machinery and equipment |
53,017 | 48,378 | ||||||
Computer software |
26,147 | 25,154 | ||||||
Furniture and fixtures |
45,133 | 41,711 | ||||||
Projects under development |
17,865 | 14,574 | ||||||
Total properties and equipment |
190,539 | 178,651 | ||||||
Less accumulated depreciation |
(115,181 | ) | (101,689 | ) | ||||
Net properties and equipment |
$ | 75,358 | $ | 76,962 | ||||
The net book value of computer software at December 31, 2009 and 2008, was $9.1
million and $5.6 million, respectively. Depreciation expense for computer software was $4.2
million, $4.3 million and $4.4 million for the years ended December 31, 2009, 2008 and 2007,
respectively.
13. | Lease Arrangements |
We have operating leases that cover our corporate office headquarters, various warehouse
and office facilities, office equipment and transportation equipment. The remaining terms of
these leases range from one year to eight years, and in most cases we expect that these leases
will be renewed or replaced by other leases in the normal course of business. We have no
significant capital leases as of December 31, 2009 or 2008.
23
Chemed Corporation and Subsidiary Companies
The following is a summary of future minimum rental payments and sublease rentals to be
received under operating leases that have initial or remaining noncancelable terms in excess of
one year at December 31, 2009 (in thousands):
2010 |
$ | 16,579 | ||
2011 |
12,659 | |||
2012 |
9,288 | |||
2013 |
6,991 | |||
2014 |
4,207 | |||
Thereafter |
3,669 | |||
Total minimum rental payments |
53,393 | |||
Less: minimum sublease rentals |
(123 | ) | ||
Net minimum rental payments |
$ | 53,270 | ||
Total rental expense incurred under operating leases for continuing operations follows
(in thousands):
For the Years Ended December 31, | ||||||||||||
2009 | 2008 | 2007 | ||||||||||
Total rental payments |
$ | 21,219 | $ | 18,867 | $ | 17,307 | ||||||
Less sublease rentals |
(270 | ) | (265 | ) | (260 | ) | ||||||
Net rental expense |
$ | 20,949 | $ | 18,602 | $ | 17,047 | ||||||
14. | Pension and Retirement Plans |
Retirement obligations under various plans cover substantially all full-time employees who
meet age and/or service eligibility requirements. The major plans providing retirement benefits
to our employees are defined contribution plans. Expenses charged to continuing operations for
our retirement and profit-sharing plans, excess benefit plans and other similar plans were $15.1
million, $2.7 million and $12.8 million for the years ended December 31, 2009, 2008 and 2007,
respectively. These expenses include the impact of market gains and losses on assets held in
deferred compensation plans.
We have excess benefit plans for key employees whose participation in the qualified plans
is limited by U.S. Employee Retirement Income Security Act requirements. Benefits are determined
based on theoretical participation in the qualified plans. Benefits are only invested in mutual
funds, and participants are not permitted to diversify accumulated benefits in shares of our
stock. Trust assets invested in shares of our stock are included in treasury stock, and the
corresponding liability is included in a separate component of stockholders equity. At December
31, 2009, these trusts held 102,027 shares or $1.9 million of our stock (2008 108,416 shares
or $2.0 million). The diversified assets of our excess benefit and deferred compensation plans,
all of which are invested in various mutual funds, totaled $24.2 million at December 31, 2009
(2008 $22.6 million).
24
Chemed Corporation and Subsidiary Companies
15. | Earnings Per Share |
The computation of earnings per share follows (in thousands, except per share data):
Income from Continuing Operations | Net Income | |||||||||||||||||||||||
For the Years Ended | Earnings | Earnings | ||||||||||||||||||||||
December 31, | Income | Shares | per Share | Income | Shares | per Share | ||||||||||||||||||
2009 |
||||||||||||||||||||||||
Earnings |
$ | 74,037 | 22,451 | $ | 3.30 | $ | 73,784 | 22,451 | $ | 3.29 | ||||||||||||||
Dilutive stock options |
| 229 | | 229 | ||||||||||||||||||||
Nonvested stock awards |
| 62 | | 62 | ||||||||||||||||||||
Diluted earnings |
$ | 74,037 | 22,742 | $ | 3.26 | $ | 73,784 | 22,742 | $ | 3.24 | ||||||||||||||
2008 |
||||||||||||||||||||||||
Earnings |
$ | 68,369 | 23,058 | $ | 2.97 | $ | 67,281 | 23,058 | $ | 2.92 | ||||||||||||||
Dilutive stock options |
| 287 | | 287 | ||||||||||||||||||||
Nonvested stock awards |
| 29 | | 29 | ||||||||||||||||||||
Diluted earnings |
$ | 68,369 | 23,374 | $ | 2.93 | $ | 67,281 | 23,374 | $ | 2.88 | ||||||||||||||
2007 |
||||||||||||||||||||||||
Earnings |
$ | 60,440 | 24,520 | $ | 2.46 | $ | 61,641 | 24,520 | $ | 2.51 | ||||||||||||||
Dilutive stock options |
| 456 | | 456 | ||||||||||||||||||||
Nonvested stock awards |
| 101 | | 101 | ||||||||||||||||||||
Diluted earnings |
$ | 60,440 | 25,077 | $ | 2.41 | $ | 61,641 | 25,077 | $ | 2.46 | ||||||||||||||
During 2009, 819,917 stock options were excluded from the computation of diluted
earnings per share as their exercise prices were greater than the average market price during
most of the year. During 2008, 827,917 stock options were so excluded. During 2007, 290,096
stock options were so excluded.
Diluted earnings per share may be impacted in future periods as the result of the issuance
of our $200 million Notes and related purchased call options and sold warrants. Per FASBs
authoritative guidance on the effect of contingently convertible instruments on diluted earnings
per share and convertible bonds with issuer option to settle for cash upon conversion, we will
not include any shares related to the Notes in our calculation of diluted earnings per share
until our average stock price for a quarter exceeds the current conversion price. We would then
include in our diluted earnings per share calculation those shares issuable using the treasury
stock method. The amount of shares issuable is based upon the amount by which the average stock
price for the quarter exceeds the conversion price. The purchased call option does not impact
the calculation of diluted earnings per share, as it is always anti-dilutive. The sold warrants
become dilutive when our average stock price for a quarter exceeds the strike price of the
warrant.
25
Chemed Corporation and Subsidiary Companies
The following table provides examples of how changes in our stock price impact the number
of shares that would be included in our diluted earnings per share calculation. It also shows
the impact on the number of shares issuable upon conversion of the Notes and settlement of the
purchased call options and sold warrants:
Shares | Total Treasury | Shares Due | Incremental | |||||||||||||||||||||
Underlying 1.875% | Method | to the Company | Shares Issued by | |||||||||||||||||||||
Share | Convertible | Warrant | Incremental | under Notes | the Company | |||||||||||||||||||
Price | Notes | Shares | Shares (a) | Hedges | upon Conversion (b) | |||||||||||||||||||
$ | 80.73 | 6,411 | | 6,411 | (6,858 | ) | (447 | ) | ||||||||||||||||
$ | 90.73 | 255,949 | | 255,949 | (273,807 | ) | (17,858 | ) | ||||||||||||||||
$ | 100.73 | 461,080 | | 461,080 | (493,250 | ) | (32,170 | ) | ||||||||||||||||
$ | 110.73 | 629,160 | 118,682 | 747,842 | (673,057 | ) | 74,785 | |||||||||||||||||
$ | 120.73 | 769,396 | 314,621 | 1,084,017 | (823,077 | ) | 260,940 | |||||||||||||||||
$ | 130.73 | 888,178 | 480,584 | 1,368,762 | (950,146 | ) | 418,616 |
a) | Represents the number of incremental shares that must be included in the calculation of fully diluted shares under U.S. GAAP. | |
b) | Represents the number of incremental shares to be issued by the Company upon conversion of the Notes assuming concurrent settlement of the note hedges and warrants. |
16. | Financial Instruments |
We adopted the provisions of the FASBs authoritative guidance on fair value measurements.
This statement defines a hierarchy which prioritizes the inputs in fair value measurements.
Level 1 measurements are measurements using quoted prices in active markets for identical assets
or liabilities. Level 2 measurements use significant other observable inputs. Level 3
measurements are measurements using significant unobservable inputs which require a company to
develop its own assumptions. In recording the fair value of assets and liabilities, companies
must use the most reliable measurement available. There was no impact on our financial position
or results of operations upon partial adoption of this authoritative guidance.
The following shows the carrying value, fair value and the hierarchy for our financial
instruments as of
December 31, 2009 (in thousands):
Fair Value Measure | ||||||||||||||||
Quoted Prices in | Significant | |||||||||||||||
Active Markets | Other | Significant | ||||||||||||||
for Identical | Observable | Unobservable | ||||||||||||||
Carrying Value | Assets (Level 1) | Inputs (Level 2) | Inputs (Level 3) | |||||||||||||
Mutual fund
investments of
deferred
compensation plans
held in trust |
$ | 24,158 | $ | 24,158 | $ | | $ | | ||||||||
Long-term debt |
152,127 | 163,587 | | |
For cash and cash equivalents, accounts receivable and accounts payable, the carrying
amount is a reasonable estimate of fair value because of the liquidity and short-term nature of
these instruments.
17. | Loans Receivable from Independent Contractors |
At December 31, 2009, we had contractual arrangements with 62 independent contractors to
provide plumbing repair and drain cleaning services under sublicensing agreements using the
Roto-Rooter name in lesser-populated areas of the United States and Canada. The arrangements
give the independent contractors the right to conduct a plumbing and drain cleaning business
using the Roto-Rooter name in a specified territory in exchange for a royalty based on a
percentage of labor sales, generally approximately 40%. We also pay for certain telephone
directory advertising in these areas, lease certain capital equipment and provide operating
manuals to serve as resources for operating a plumbing and drain cleaning business. The
contracts are generally cancelable upon 90 days written notice (without cause) or upon a few
days notice (with cause). The independent contractors are responsible for running the
businesses as they believe best.
Our maximum exposure to loss from arrangements with our independent contractors at
December 31, 2009 is approximately $1.3 million (2008 $1.6 million). The exposure to loss is
mainly the result of loans provided to the
26
Chemed Corporation and Subsidiary Companies
independent contractors. In most cases, these loans are partially secured by receivables and
equipment owned by the independent contractor. The interest rates on the loans range from zero
to 8% per annum, and the remaining terms of the loans range from 2.5 months to 5.4 years at
December 31, 2009. During 2009, we recorded revenues of $21.6 million (2008 $22.0 million;
2007 $22.1 million) and pretax profits of $9.5 million (2008 $9.5 million; 2007 $9.0
million) from our independent contractors.
18. | Litigation |
VITAS is party to a class action lawsuit filed in the Superior Court of California, Los
Angeles County, in September 2006 by Bernadette Santos, Keith Knoche and Joyce White (Santos).
This case alleges failure to pay overtime and failure to provide meal and rest periods to a
purported class of California admissions nurses, chaplains and sales representatives. The case
seeks payment of penalties, interest and Plaintiffs attorney fees. VITAS contests these
allegations. In December 2009, the trial court denied Plaintiffs motion for class
certification. The lawsuit is in its early stages and we are unable to estimate our potential
liability, if any, with respect to these allegations.
Regardless of outcome, defense of litigation adversely affects us through defense costs,
diversion of our time and related publicity. In the normal course of business, we are a party
to various claims and legal proceedings. We record a reserve for these matters when an adverse
outcome is probable and the amount of the potential liability is reasonably estimable.
19. | Regulatory Matters |
In April 2005, the Office of Inspector General (OIG) for the Department of Health and
Human Services served VITAS with civil subpoenas relating to VITAS alleged failure to
appropriately bill Medicare and Medicaid for hospice services. As part of this investigation,
the OIG selected medical records for 320 past and current patients from VITAS three largest
programs for review. It also sought policies and procedures dating back to 1998 covering
admissions, certifications, recertifications and discharges. During the third quarter of 2005
and again in May 2006, the OIG requested additional information from us. The Court dismissed a
related qui tam complaint filed in U.S. District Court for the Southern District of Florida with
prejudice in July 2007. The plaintiffs appealed this dismissal, which the Court of Appeals
affirmed. The government continues to investigate the complaints allegations. In March 2009,
we received a letter from the government reiterating the basis of their investigation.
In May 2009, VITAS received an administrative subpoena from the U.S. Department of Justice
requesting VITAS deliver to the OIG documents, patient records, and policy and procedure manuals
for headquarters and its Texas programs concerning hospice services provided for the period
January 1, 2003 to the date of the letter. In August 2009, the OIG selected medical records for
59 past and current patients from a Texas program for review. In February 2010, VITAS received
a companion civil investigative demand from the state of Texas Attorney Generals Office,
seeking related documents. Based on the early stage of the investigation and the limited
information we have at this time, we cannot predict the outcome of this investigation. We
believe that we are in material compliance with Medicare and Medicaid rules and regulations
applicable to hospice providers.
The costs to comply with either of these investigations were not material for any period
presented. We are unable to predict the outcome of these matters or the impact, if any, that
the investigation may have on our business, results of operations, liquidity or capital
resources. Regardless of outcome, responding to the subpoenas can adversely affect us through
defense costs, diversion of our time and related publicity.
20. | Related Party Transactions |
VITAS has two pharmacy services agreements (Agreements) with Omnicare, Inc. and its
subsidiaries (OCR) whereby OCR provides specified pharmacy services for VITAS and its hospice
patients in geographical areas served by both VITAS and OCR. The Agreements renew automatically
for one-year terms. Either party may cancel the Agreements at the end of any term by giving 90
days prior written notice. VITAS made purchases from OCR of $33.1 million, $32.9 million and
$33.6 million for the years ended December 31, 2009, 2008 and 2007, respectively. VITAS
accounts payable to OCR and its subsidiaries are not material at December 31, 2009 and 2008.
Mr. Joel F. Gemunder, President and Chief Executive Officer of OCR., and Ms. Andrea Lindell
are directors of both OCR and the Company. Mr. Kevin J. McNamara, President, Chief Executive
Officer and a director of the Company, is a director emeritus of OCR. We believe that the terms
of these agreements are no less favorable to VITAS than we could negotiate with an unrelated
party.
27
Chemed Corporation and Subsidiary Companies
21. | Capital Stock Transactions |
On April 26, 2007, our Board of Directors authorized a $150 million stock repurchase
program. On May 19, 2008 our Board of Directors authorized an additional $56 million to the
April 2007 stock repurchase program. For the year ended December 31, 2009, we repurchased
15,900 shares at a weighted average cost per share of $46.65 under the April 2007 program. For
the year ended December 31, 2008, we repurchased 1.7 million shares at a weighted average cost
per share of $39.73 under the April 2007 program.
28
Chemed Corporation and Subsidiary Companies
22. Guarantor Subsidiaries
Our 1.875% Senior Convertible Notes issued on May 14, 2007, are fully and unconditionally
guaranteed on an unsecured, joint and severally liable basis by our 100% owned subsidiaries. The
equity method has been used with respect to the parent companys (Chemed) investment in
subsidiaries. No consolidating adjustment column is presented for the condensed consolidating
statement of cash flow since there were no signficant consolidating entries for the periods
presented. The following condensed, consolidating financial data present the composition of the
parent company, the guarantor subsidiaries and the non-guarantor subsidiaries as of December 31,
2009 and 2008, and for the years ended December 31, 2009, 2008 and 2007 (in thousands):
Guarantor | Non-Guarantor | Consolidating | ||||||||||||||||||
December 31, 2009 | Parent | Subsidiaries | Subsidiaries | Adjustments | Consolidated | |||||||||||||||
ASSETS |
||||||||||||||||||||
Cash and cash equivalents |
$ | 109,331 | $ | (1,221 | ) | $ | 4,306 | $ | | $ | 112,416 | |||||||||
Accounts receivable, less allowances |
618 | 52,303 | 540 | | 53,461 | |||||||||||||||
Intercompany receivables |
| 149,888 | | (149,888 | ) | | ||||||||||||||
Inventories |
| 7,009 | 534 | | 7,543 | |||||||||||||||
Current deferred income taxes |
(378 | ) | 14,048 | 31 | | 13,701 | ||||||||||||||
Prepaid expenses |
(2,457 | ) | 13,706 | (112 | ) | | 11,137 | |||||||||||||
Total current assets |
107,114 | 235,733 | 5,299 | (149,888 | ) | 198,258 | ||||||||||||||
Investments of deferred compensation plans held in trust |
| | 24,158 | | 24,158 | |||||||||||||||
Properties and equipment, at cost, less accumulated
depreciation |
10,309 | 62,912 | 2,137 | | 75,358 | |||||||||||||||
Identifiable intangible assets less accumulated amortization |
| 57,920 | | | 57,920 | |||||||||||||||
Goodwill |
| 445,662 | 4,380 | | 450,042 | |||||||||||||||
Other assets |
11,190 | 2,232 | 312 | | 13,734 | |||||||||||||||
Investments in subsidiaries |
643,572 | 15,523 | | (659,095 | ) | | ||||||||||||||
Total assets |
$ | 772,185 | $ | 819,982 | $ | 36,286 | $ | (808,983 | ) | $ | 819,470 | |||||||||
LIABILITIES AND STOCKHOLDERS EQUITY |
||||||||||||||||||||
Accounts payable |
$ | (2,411 | ) | $ | 54,084 | $ | 398 | $ | | $ | 52,071 | |||||||||
Intercompany payables |
147,744 | | 2,144 | (149,888 | ) | | ||||||||||||||
Income taxes |
(2,145 | ) | 2,159 | 49 | | 63 | ||||||||||||||
Accrued insurance |
1,231 | 33,930 | | | 35,161 | |||||||||||||||
Accrued compensation |
4,235 | 30,020 | 407 | | 34,662 | |||||||||||||||
Other current liabilities |
1,643 | 11,367 | 1,117 | | 14,127 | |||||||||||||||
Total current liabilities |
150,297 | 131,560 | 4,115 | (149,888 | ) | 136,084 | ||||||||||||||
Deferred income taxes |
(10,549 | ) | 43,183 | (6,710 | ) | | 25,924 | |||||||||||||
Long-term debt |
152,127 | | | | 152,127 | |||||||||||||||
Deferred compensation liabilities |
| | 23,637 | | 23,637 | |||||||||||||||
Other liabilities |
3,148 | 1,388 | | | 4,536 | |||||||||||||||
Stockholders equity |
477,162 | 643,851 | 15,244 | (659,095 | ) | 477,162 | ||||||||||||||
Total liabilities and stockholders equity |
$ | 772,185 | $ | 819,982 | $ | 36,286 | $ | (808,983 | ) | $ | 819,470 | |||||||||
Guarantor | Non-Guarantor | Consolidating | ||||||||||||||||||
December 31, 2008 | Parent | Subsidiaries | Subsidiaries | Adjustments | Consolidated | |||||||||||||||
ASSETS |
||||||||||||||||||||
Cash and cash equivalents |
$ | 65 | $ | 202 | $ | 3,361 | $ | | $ | 3,628 | ||||||||||
Accounts receivable, less allowances |
1,261 | 96,112 | 703 | | 98,076 | |||||||||||||||
Intercompany receivables |
| 37,105 | | (37,105 | ) | | ||||||||||||||
Inventories |
| 7,021 | 548 | | 7,569 | |||||||||||||||
Current deferred income taxes |
(229 | ) | 15,511 | 110 | | 15,392 | ||||||||||||||
Prepaid expenses |
2,296 | 7,982 | 990 | | 11,268 | |||||||||||||||
Total current assets |
3,393 | 163,933 | 5,712 | (37,105 | ) | 135,933 | ||||||||||||||
Investments of deferred compensation plans held in trust |
| | 22,628 | | 22,628 | |||||||||||||||
Properties and equipment, at cost, less accumulated
depreciation |
11,665 | 63,179 | 2,118 | | 76,962 | |||||||||||||||
Identifiable intangible assets less accumulated amortization |
| 61,303 | | | 61,303 | |||||||||||||||
Goodwill |
| 444,433 | 4,288 | | 448,721 | |||||||||||||||
Other assets |
11,312 | 2,455 | 308 | | 14,075 | |||||||||||||||
Investments in subsidiaries |
568,038 | 11,196 | | (579,234 | ) | | ||||||||||||||
Total assets |
$ | 594,408 | $ | 746,499 | $ | 35,054 | $ | (616,339 | ) | $ | 759,622 | |||||||||
LIABILITIES AND STOCKHOLDERS EQUITY |
||||||||||||||||||||
Accounts payable |
$ | (1,688 | ) | $ | 54,175 | $ | 323 | $ | | $ | 52,810 | |||||||||
Intercompany payables |
29,513 | | 7,592 | (37,105 | ) | | ||||||||||||||
Current portion of long-term debt |
10,000 | 169 | | | 10,169 | |||||||||||||||
Income taxes |
(1,940 | ) | 3,909 | 212 | | 2,181 | ||||||||||||||
Accrued insurance |
1,425 | 34,569 | | | 35,994 | |||||||||||||||
Accrued compensation |
3,817 | 36,523 | 401 | | 40,741 | |||||||||||||||
Other current liabilities |
2,022 | 8,979 | 1,179 | | 12,180 | |||||||||||||||
Total current liabilities |
43,149 | 138,324 | 9,707 | (37,105 | ) | 154,075 | ||||||||||||||
Deferred income taxes |
(7,801 | ) | 38,310 | (8,032 | ) | | 22,477 | |||||||||||||
Long-term debt |
158,210 | | | | 158,210 | |||||||||||||||
Deferred compensation liabilities |
| | 22,417 | | 22,417 | |||||||||||||||
Other liabilities |
4,019 | 1,593 | | | 5,612 | |||||||||||||||
Stockholders equity |
396,831 | 568,272 | 10,962 | (579,234 | ) | 396,831 | ||||||||||||||
Total liabilities and stockholders equity |
$ | 594,408 | $ | 746,499 | $ | 35,054 | $ | (616,339 | ) | $ | 759,622 | |||||||||
29
Chemed Corporation and Subsidiary Companies
Guarantor | Non-Guarantor | Consolidating | ||||||||||||||||||
For the year ended December 31, 2009 | Parent | Subsidiaries | Subsidiaries | Adjustments | Consolidated | |||||||||||||||
Continuing Operations |
||||||||||||||||||||
Net sales and service revenues |
$ | | $ | 1,166,972 | $ | 23,264 | $ | | $ | 1,190,236 | ||||||||||
Cost of services provided and goods sold |
| 822,788 | 11,786 | | 834,574 | |||||||||||||||
Selling, general and administrative
expenses |
23,199 | 163,600 | 10,627 | | 197,426 | |||||||||||||||
Depreciation |
602 | 20,221 | 712 | | 21,535 | |||||||||||||||
Amortization |
2,294 | 4,073 | | | 6,367 | |||||||||||||||
Other operating expenses |
3,989 | | | | 3,989 | |||||||||||||||
Total costs and expenses |
30,084 | 1,010,682 | 23,125 | | 1,063,891 | |||||||||||||||
Income/ (loss) from operations |
(30,084 | ) | 156,290 | 139 | | 126,345 | ||||||||||||||
Interest expense |
(11,040 | ) | (565 | ) | 6 | | (11,599 | ) | ||||||||||||
Other (expense)/income net |
5,428 | (5,422 | ) | 5,868 | | 5,874 | ||||||||||||||
Income/ (loss) before income taxes |
(35,696 | ) | 150,303 | 6,013 | | 120,620 | ||||||||||||||
Income tax (provision)/ benefit |
12,463 | (56,948 | ) | (2,098 | ) | | (46,583 | ) | ||||||||||||
Equity in net income of subsidiaries |
97,270 | 4,043 | | (101,313 | ) | | ||||||||||||||
Income from continuing operations |
74,037 | 97,398 | 3,915 | (101,313 | ) | 74,037 | ||||||||||||||
Discontinued Operations |
(253 | ) | | | | (253 | ) | |||||||||||||
Net income |
$ | 73,784 | $ | 97,398 | $ | 3,915 | $ | (101,313 | ) | $ | 73,784 | |||||||||
Guarantor | Non-Guarantor | Consolidating | ||||||||||||||||||
For the year ended December 31, 2008 | Parent | Subsidiaries | Subsidiaries | Adjustments | Consolidated | |||||||||||||||
Continuing Operations |
||||||||||||||||||||
Net sales and service revenues |
$ | | $ | 1,124,063 | $ | 24,878 | $ | | $ | 1,148,941 | ||||||||||
Cost of services provided and goods sold |
| 798,173 | 12,374 | | 810,547 | |||||||||||||||
Selling, general and administrative
expenses |
19,644 | 158,214 | (2,525 | ) | | 175,333 | ||||||||||||||
Depreciation |
504 | 20,382 | 695 | | 21,581 | |||||||||||||||
Amortization |
1,890 | 4,034 | | | 5,924 | |||||||||||||||
Other operating expenses |
2,699 | | | | 2,699 | |||||||||||||||
Total costs and expenses |
24,737 | 980,803 | 10,544 | | 1,016,084 | |||||||||||||||
Income/ (loss) from operations |
(24,737 | ) | 143,260 | 14,334 | | 132,857 | ||||||||||||||
Interest expense |
(11,722 | ) | (398 | ) | (3 | ) | | (12,123 | ) | |||||||||||
Gain on extinguishment of debt |
3,406 | | | | 3,406 | |||||||||||||||
Other (expense)/income net |
4,381 | (4,070 | ) | (9,047 | ) | | (8,736 | ) | ||||||||||||
Income/ (loss) before income taxes |
(28,672 | ) | 138,792 | 5,284 | | 115,404 | ||||||||||||||
Income tax (provision)/ benefit |
10,386 | (52,199 | ) | (5,222 | ) | | (47,035 | ) | ||||||||||||
Equity in net income of subsidiaries |
86,655 | 1,403 | | (88,058 | ) | | ||||||||||||||
Income from continuing operations |
68,369 | 87,996 | 62 | (88,058 | ) | 68,369 | ||||||||||||||
Discontinued Operations |
(1,088 | ) | | | | (1,088 | ) | |||||||||||||
Net income |
$ | 67,281 | $ | 87,996 | $ | 62 | $ | (88,058 | ) | $ | 67,281 | |||||||||
Guarantor | Non-Guarantor | Consolidating | ||||||||||||||||||
For the year ended December 31, 2007 | Parent | Subsidiaries | Subsidiaries | Adjustments | Consolidated | |||||||||||||||
Continuing Operations |
||||||||||||||||||||
Net sales and service revenues |
$ | | $ | 1,075,042 | $ | 25,016 | $ | | $ | 1,100,058 | ||||||||||
Cost of services provided and goods sold |
| 754,739 | 12,327 | | 767,066 | |||||||||||||||
Selling, general and administrative
expenses |
18,846 | 159,074 | 6,140 | | 184,060 | |||||||||||||||
Depreciation |
488 | 19,003 | 627 | | 20,118 | |||||||||||||||
Amortization |
1,232 | 4,036 | 2 | | 5,270 | |||||||||||||||
Other operating expenses/(income) |
(1,138 | ) | 1,927 | | | 789 | ||||||||||||||
Total costs and expenses |
19,428 | 938,779 | 19,096 | | 977,303 | |||||||||||||||
Income/ (loss) from operations |
(19,428 | ) | 136,263 | 5,920 | | 122,755 | ||||||||||||||
Interest expense |
(14,287 | ) | (445 | ) | (189 | ) | | (14,921 | ) | |||||||||||
Loss on extinguishment of debt |
(13,798 | ) | | | | (13,798 | ) | |||||||||||||
Other (expense)/income net |
15,030 | (10,809 | ) | (96 | ) | | 4,125 | |||||||||||||
Income/ (loss) before income taxes |
(32,483 | ) | 125,009 | 5,635 | | 98,161 | ||||||||||||||
Income tax (provision)/ benefit |
11,428 | (46,782 | ) | (2,367 | ) | | (37,721 | ) | ||||||||||||
Equity in net income of subsidiaries |
82,696 | 3,453 | | (86,149 | ) | | ||||||||||||||
Income from continuing operations |
61,641 | 81,680 | 3,268 | (86,149 | ) | 60,440 | ||||||||||||||
Discontinued Operations |
| 1,201 | | | 1,201 | |||||||||||||||
Net income |
$ | 61,641 | $ | 82,881 | $ | 3,268 | $ | (86,149 | ) | $ | 61,641 | |||||||||
30
Chemed Corporation and Subsidiary Companies
Guarantor | Non-Guarantor | |||||||||||||||
For the year ended December 31, 2009 | Parent | Subsidiaries | Subsidiaries | Consolidated | ||||||||||||
Cash Flow from Operating Activities: |
||||||||||||||||
Net cash provided by operating activities |
$ | 950 | $ | 153,387 | $ | 6,495 | $ | 160,832 | ||||||||
Cash Flow from Investing Activities: |
||||||||||||||||
Capital expenditures |
(448 | ) | (20,394 | ) | (654 | ) | (21,496 | ) | ||||||||
Business combinations, net of cash acquired |
| (1,919 | ) | | (1,919 | ) | ||||||||||
Net payments from sale of discontinued operations |
(328 | ) | (302 | ) | | (630 | ) | |||||||||
Proceeds from sale of property and equipment |
1,285 | 292 | | 1,577 | ||||||||||||
Other sources/(uses) net |
(255 | ) | (302 | ) | 183 | (374 | ) | |||||||||
Net cash provided/(used) by investing activities |
254 | (22,625 | ) | (471 | ) | (22,842 | ) | |||||||||
Cash Flow from Financing Activities: |
||||||||||||||||
Change in cash overdrafts payable |
19 | 2,872 | | 2,891 | ||||||||||||
Change in intercompany accounts |
140,674 | (135,226 | ) | (5,448 | ) | | ||||||||||
Dividends paid to shareholders |
(8,157 | ) | | | (8,157 | ) | ||||||||||
Purchases of treasury stock |
(4,225 | ) | | | (4,225 | ) | ||||||||||
Proceeds from exercise of stock options |
545 | | | 545 | ||||||||||||
Realized excess tax benefit on share based compensation |
1,955 | | | 1,955 | ||||||||||||
Net decrease in revolving line of credit |
(8,200 | ) | | | (8,200 | ) | ||||||||||
Repayment of long-term debt |
(14,500 | ) | (169 | ) | | (14,669 | ) | |||||||||
Other sources/(uses) net |
(49 | ) | 338 | 369 | 658 | |||||||||||
Net cash provided/ (used) by financing activities |
108,062 | (132,185 | ) | (5,079 | ) | (29,202 | ) | |||||||||
Net increase/(decrease) in cash and cash equivalents |
109,266 | (1,423 | ) | 945 | 108,788 | |||||||||||
Cash and cash equivalents at beginning of year |
65 | 202 | 3,361 | 3,628 | ||||||||||||
Cash and cash equivalents at end of period |
$ | 109,331 | $ | (1,221 | ) | $ | 4,306 | $ | 112,416 | |||||||
Guarantor | Non-Guarantor | |||||||||||||||
For the year ended December 31, 2008 | Parent | Subsidiaries | Subsidiaries | Consolidated | ||||||||||||
Cash Flow from Operating Activities: |
||||||||||||||||
Net cash provided/(used) by operating activities |
$ | (8,912 | ) | $ | 118,904 | $ | 2,091 | $ | 112,083 | |||||||
Cash Flow from Investing Activities: |
||||||||||||||||
Capital expenditures |
(9,492 | ) | (15,576 | ) | (1,026 | ) | (26,094 | ) | ||||||||
Business combinations, net of cash acquired |
| (11,200 | ) | | (11,200 | ) | ||||||||||
Net proceeds from sale of discontinued operations |
8,824 | | | 8,824 | ||||||||||||
Proceeds from sale of property and equipment |
10 | 342 | 35 | 387 | ||||||||||||
Other sources/(uses) net |
(660 | ) | 123 | (7 | ) | (544 | ) | |||||||||
Net cash used by investing activities |
(1,318 | ) | (26,311 | ) | (998 | ) | (28,627 | ) | ||||||||
Cash Flow from Financing Activities: |
||||||||||||||||
Change in cash overdrafts payable |
(1,106 | ) | 250 | | (856 | ) | ||||||||||
Change in intercompany accounts |
90,906 | (91,249 | ) | 343 | | |||||||||||
Dividends paid to shareholders |
(5,543 | ) | | | (5,543 | ) | ||||||||||
Purchases of treasury stock |
(69,788 | ) | | | (69,788 | ) | ||||||||||
Proceeds from exercise of stock options |
291 | | | 291 | ||||||||||||
Realized excess tax benefit on share based compensation |
2,422 | | | 2,422 | ||||||||||||
Net increase in revolving line of credit |
8,200 | | | 8,200 | ||||||||||||
Repayment of long-term debt |
(18,551 | ) | (162 | ) | | (18,713 | ) | |||||||||
Other sources/(uses) net |
(413 | ) | 354 | (770 | ) | (829 | ) | |||||||||
Net cash provided/ (used) by financing activities |
6,418 | (90,807 | ) | (427 | ) | (84,816 | ) | |||||||||
Net increase/(decrease) in cash and cash equivalents |
(3,812 | ) | 1,786 | 666 | (1,360 | ) | ||||||||||
Cash and cash equivalents at beginning of year |
3,877 | (1,584 | ) | 2,695 | 4,988 | |||||||||||
Cash and cash equivalents at end of period |
$ | 65 | $ | 202 | $ | 3,361 | $ | 3,628 | ||||||||
Guarantor | Non-Guarantor | |||||||||||||||
For the year ended December 31, 2007 | Parent | Subsidiaries | Subsidiaries | Consolidated | ||||||||||||
Cash Flow from Operating Activities: |
||||||||||||||||
Net cash provided by operating activities |
$ | 93 | $ | 97,008 | $ | 2,483 | $ | 99,584 | ||||||||
Cash Flow from Investing Activities: |
||||||||||||||||
Capital expenditures |
(193 | ) | (25,674 | ) | (773 | ) | (26,640 | ) | ||||||||
Business combinations, net of cash acquired |
| (1,079 | ) | | (1,079 | ) | ||||||||||
Net proceeds/(payments) from sale of discontinued operations |
2,502 | (7,904 | ) | | (5,402 | ) | ||||||||||
Proceeds from sale of property and equipment |
2,963 | 116 | 25 | 3,104 | ||||||||||||
Other uses net |
(919 | ) | (751 | ) | (31 | ) | (1,701 | ) | ||||||||
Net cash provided/(used) by investing activities |
4,353 | (35,292 | ) | (779 | ) | (31,718 | ) | |||||||||
Cash Flow from Financing Activities: |
||||||||||||||||
Change in cash overdrafts payable |
7 | (926 | ) | | (919 | ) | ||||||||||
Change in intercompany accounts |
66,095 | (62,296 | ) | (3,799 | ) | | ||||||||||
Dividends (paid)/received to/from shareholders |
(5,888 | ) | 1,446 | (1,446 | ) | (5,888 | ) | |||||||||
Purchases of treasury stock |
(131,704 | ) | | | (131,704 | ) | ||||||||||
Proceeds from exercise of stock options |
2,467 | | | 2,467 | ||||||||||||
Realized excess tax benefit on share based compensation |
3,091 | | | 3,091 | ||||||||||||
Purchase note hedges |
(55,100 | ) | | | (55,100 | ) | ||||||||||
Proceeds from issuance of warrants |
27,614 | | | 27,614 | ||||||||||||
Proceeds from issuance of long-term debt |
245,106 | | | 245,106 | ||||||||||||
Proceeds from conversion feature of debt, net of costs |
53,206 | | | 53,206 | ||||||||||||
Debt issuance costs |
(5,261 | ) | | | (5,261 | ) | ||||||||||
Repayment of long-term debt |
(225,500 | ) | (209 | ) | | (225,709 | ) | |||||||||
Other sources/(uses) net |
40 | (1 | ) | 906 | 945 | |||||||||||
Net cash used by financing activities |
(25,827 | ) | (61,986 | ) | (4,339 | ) | (92,152 | ) | ||||||||
Net decrease in cash and cash equivalents |
(21,381 | ) | (270 | ) | (2,635 | ) | (24,286 | ) | ||||||||
Cash and cash equivalents at beginning of year |
25,258 | (1,314 | ) | 5,330 | 29,274 | |||||||||||
Cash and cash equivalents at end of period |
$ | 3,877 | $ | (1,584 | ) | $ | 2,695 | $ | 4,988 | |||||||
31
Chemed Corporation and Subsidiary Companies
UNAUDITED SUMMARY OF QUARTERLY RESULTS
Chemed Corporation and Subsidiary Companies
(in thousands, except per share and footnote data)
(in thousands, except per share and footnote data)
First | Second | Third | Fourth | Total | ||||||||||||||||
For the Year Ended December 31, 2009 | Quarter | Quarter | Quarter | Quarter | Year | |||||||||||||||
Continuing Operations |
||||||||||||||||||||
Total service revenues and sales |
$ | 294,938 | $ | 295,255 | $ | 296,794 | $ | 303,249 | $ | 1,190,236 | ||||||||||
Gross profit |
$ | 87,925 | $ | 87,918 | $ | 87,906 | $ | 91,913 | $ | 355,662 | ||||||||||
Income from operations |
$ | 34,726 | $ | 27,938 | $ | 32,786 | $ | 30,895 | $ | 126,345 | ||||||||||
Interest expense |
(2,844 | ) | (3,142 | ) | (2,853 | ) | (2,760 | ) | (11,599 | ) | ||||||||||
Other income/(expense)net |
(276 | ) | 3,358 | 1,733 | 1,059 | 5,874 | ||||||||||||||
Income before income taxes |
31,606 | 28,154 | 31,666 | 29,194 | 120,620 | |||||||||||||||
Income taxes |
(12,267 | ) | (10,904 | ) | (12,456 | ) | (10,956 | ) | (46,583 | ) | ||||||||||
Income from continuing operations (a) |
19,339 | 17,250 | 19,210 | 18,238 | 74,037 | |||||||||||||||
Discontinued Operations |
| | | (253 | ) | (253 | ) | |||||||||||||
Net Income (a) |
$ | 19,339 | $ | 17,250 | $ | 19,210 | $ | 17,985 | $ | 73,784 | ||||||||||
Earnings Per Share (a) |
||||||||||||||||||||
Income from continuing operations |
$ | 0.86 | $ | 0.77 | $ | 0.86 | $ | 0.81 | $ | 3.30 | ||||||||||
Net income |
$ | 0.86 | $ | 0.77 | $ | 0.86 | $ | 0.80 | $ | 3.29 | ||||||||||
Diluted Earnings Per Share (a) |
||||||||||||||||||||
Income from continuing operations |
$ | 0.85 | $ | 0.76 | $ | 0.84 | $ | 0.80 | $ | 3.26 | ||||||||||
Net income |
$ | 0.85 | $ | 0.76 | $ | 0.84 | $ | 0.78 | $ | 3.24 | ||||||||||
Average number of shares outstanding |
||||||||||||||||||||
Earnings per share |
22,394 | 22,417 | 22,461 | 22,551 | 22,451 | |||||||||||||||
Diluted earnings per share |
22,647 | 22,672 | 22,744 | 22,937 | 22,742 | |||||||||||||||
(a) | The following amounts are included in income from continuing operations during the respective quarter (in thousands): |
First | Second | Third | Fourth | Total | ||||||||||||||||
Quarter | Quarter | Quarter | Quarter | Year | ||||||||||||||||
Pretax (cost)/benefit: |
||||||||||||||||||||
Stock option expense |
$ | (2,042 | ) | $ | (2,443 | ) | $ | (2,214 | ) | $ | (1,940 | ) | $ | (8,639 | ) | |||||
Noncash impact of change in accounting for convertible
debt |
(1,530 | ) | (1,561 | ) | (1,591 | ) | (1,623 | ) | (6,305 | ) | ||||||||||
Non-taxable income from certain investments held in
deferred compensation trusts |
1,211 | | | | 1,211 | |||||||||||||||
Expenses associated with contested proxy solicitiation |
(545 | ) | (3,444 | ) | | | (3,989 | ) | ||||||||||||
Expenses incurred in connection with the Office
of Inspector General investigation |
(13 | ) | (86 | ) | (343 | ) | (144 | ) | (586 | ) | ||||||||||
Long-term incentive compensation |
| | | (5,007 | ) | (5,007 | ) | |||||||||||||
Costs related to litigation settlements |
| | | (882 | ) | (882 | ) | |||||||||||||
Total |
$ | (2,919 | ) | $ | (7,534 | ) | $ | (4,148 | ) | $ | (9,596 | ) | $ | (24,197 | ) | |||||
Aftertax (cost)/benefit: |
||||||||||||||||||||
Stock option expense |
$ | (1,292 | ) | $ | (1,544 | ) | $ | (1,401 | ) | $ | (1,227 | ) | $ | (5,464 | ) | |||||
Noncash impact of change in accounting for convertible
debt |
(968 | ) | (987 | ) | (1,006 | ) | (1,027 | ) | (3,988 | ) | ||||||||||
Non-taxable income from certain investments held in
deferred compensation trusts |
1,211 | | | | 1,211 | |||||||||||||||
Income tax impact of nondeductible losses on investments
held in deferred compensation trusts |
(475 | ) | 20 | | | (455 | ) | |||||||||||||
Expenses associated with contested proxy solicitiation |
(345 | ) | (2,180 | ) | | | (2,525 | ) | ||||||||||||
Expenses incurred in connection with the Office
of Inspector General investigation |
(8 | ) | (53 | ) | (213 | ) | (89 | ) | (363 | ) | ||||||||||
Long-term incentive compensation |
| | | (3,134 | ) | (3,134 | ) | |||||||||||||
Costs related to litigation settlements |
| | | (534 | ) | (534 | ) | |||||||||||||
Total |
$ | (1,877 | ) | $ | (4,744 | ) | $ | (2,620 | ) | $ | (6,011 | ) | $ | (15,252 | ) | |||||
32
Chemed Corporation and Subsidiary Companies
UNAUDITED SUMMARY OF QUARTERLY RESULTS
Chemed Corporation and Subsidiary Companies
(in thousands, except per share and footnote data)
(in thousands, except per share and footnote data)
First | Second | Third | Fourth | Total | ||||||||||||||||
For the Year Ended December 31, 2008 | Quarter | Quarter | Quarter | Quarter | Year | |||||||||||||||
Continuing Operations |
||||||||||||||||||||
Total service revenues and sales |
$ | 285,268 | $ | 283,156 | $ | 288,312 | $ | 292,205 | $ | 1,148,941 | ||||||||||
Gross profit |
$ | 79,456 | $ | 82,017 | $ | 85,866 | $ | 91,055 | $ | 338,394 | ||||||||||
Income from operations |
$ | 29,841 | $ | 28,837 | $ | 34,909 | $ | 39,270 | $ | 132,857 | ||||||||||
Interest expense |
(3,109 | ) | (2,964 | ) | (3,140 | ) | (2,910 | ) | (12,123 | ) | ||||||||||
Gain on extinguishment of debt |
| | | 3,406 | 3,406 | |||||||||||||||
Other income/(expense)net |
(1,189 | ) | 886 | (1,908 | ) | (6,525 | ) | (8,736 | ) | |||||||||||
Income before income taxes |
25,543 | 26,759 | 29,861 | 33,241 | 115,404 | |||||||||||||||
Income taxes |
(9,683 | ) | (10,488 | ) | (12,910 | ) | (13,954 | ) | (47,035 | ) | ||||||||||
Income from continuing operations
(a) |
15,860 | 16,271 | 16,951 | 19,287 | 68,369 | |||||||||||||||
Discontinued Operations |
| | | (1,088 | ) | (1,088 | ) | |||||||||||||
Net Income (a) |
$ | 15,860 | $ | 16,271 | $ | 16,951 | $ | 18,199 | $ | 67,281 | ||||||||||
Earnings Per Share (a) |
||||||||||||||||||||
Income from continuing operations |
$ | 0.66 | $ | 0.69 | $ | 0.75 | $ | 0.86 | $ | 2.97 | ||||||||||
Net income |
$ | 0.66 | $ | 0.69 | $ | 0.75 | $ | 0.81 | $ | 2.92 | ||||||||||
Diluted Earnings Per Share (a) |
||||||||||||||||||||
Income from continuing operations |
$ | 0.65 | $ | 0.68 | $ | 0.74 | $ | 0.85 | $ | 2.93 | ||||||||||
Net income |
$ | 0.65 | $ | 0.68 | $ | 0.74 | $ | 0.80 | $ | 2.88 | ||||||||||
Average number of shares outstanding |
||||||||||||||||||||
Earnings per share |
23,873 | 23,486 | 22,503 | 22,382 | 23,058 | |||||||||||||||
Diluted earnings per share |
24,285 | 23,759 | 22,818 | 22,644 | 23,374 | |||||||||||||||
(a) | The following amounts are included in income from continuing operations during the respective quarter (in thousands): |
First | Second | Third | Fourth | Total | ||||||||||||||||
Quarter | Quarter | Quarter | Quarter | Year | ||||||||||||||||
Pretax (cost)/benefit: |
||||||||||||||||||||
Stock option expense |
$ | (1,391 | ) | $ | (1,591 | ) | $ | (2,102 | ) | $ | (2,219 | ) | $ | (7,303 | ) | |||||
Noncash impact of change in accounting for convertible
debt |
(1,512 | ) | (1,542 | ) | (1,570 | ) | (1,515 | ) | (6,139 | ) | ||||||||||
Unreserved prior years insurance claim |
(597 | ) | | | | (597 | ) | |||||||||||||
Expenses incurred in connection with the Office
of Inspector General investigation |
15 | (57 | ) | (2 | ) | (2 | ) | (46 | ) | |||||||||||
Gain on extinguishment of debt |
| | | 3,406 | 3,406 | |||||||||||||||
Impairment loss on transportation equipment |
| | | (2,699 | ) | (2,699 | ) | |||||||||||||
Total |
$ | (3,485 | ) | $ | (3,190 | ) | $ | (3,674 | ) | $ | (3,029 | ) | $ | (13,378 | ) | |||||
Aftertax (cost)/benefit: |
||||||||||||||||||||
Stock option expense |
$ | (884 | ) | $ | (1,010 | ) | $ | (1,334 | ) | $ | (1,391 | ) | $ | (4,619 | ) | |||||
Noncash impact of change in accounting for convertible
debt |
(960 | ) | (979 | ) | (997 | ) | (1,070 | ) | (4,006 | ) | ||||||||||
Unreserved prior years insurance claim |
(358 | ) | | | | (358 | ) | |||||||||||||
Expenses incurred in connection with the Office
of Inspector General investigation |
9 | (35 | ) | (1 | ) | (1 | ) | (28 | ) | |||||||||||
Income tax credit related to prior years |
322 | | | | 322 | |||||||||||||||
Income tax impact of nondeductible losses on investments
held in deferred compensation trusts |
| | (1,237 | ) | (1,825 | ) | (3,062 | ) | ||||||||||||
Gain on extinguishment of debt |
| | | 2,934 | 2,934 | |||||||||||||||
Impairment loss on transportation equipment |
| | | (1,714 | ) | (1,714 | ) | |||||||||||||
Total |
$ | (1,871 | ) | $ | (2,024 | ) | $ | (3,569 | ) | $ | (3,067 | ) | $ | (10,531 | ) | |||||
33
Chemed Corporation and Subsidiary Companies
SELECTED FINANCIAL DATA
Chemed Corporation and Subsidiary Companies
(in thousands, except per share and footnote data, ratios, percentages and personnel)
(in thousands, except per share and footnote data, ratios, percentages and personnel)
2009 | 2008 | 2007 | 2006 | 2005 | ||||||||||||||||
Summary of Operations |
||||||||||||||||||||
Continuing operations (a) |
||||||||||||||||||||
Service revenues and sales |
$ | 1,190,236 | $ | 1,148,941 | $ | 1,100,058 | $ | 1,018,587 | $ | 915,970 | ||||||||||
Gross profit (excluding depreciation) |
355,662 | 338,394 | 332,992 | 288,464 | 271,494 | |||||||||||||||
Depreciation |
21,535 | 21,581 | 20,118 | 16,775 | 16,150 | |||||||||||||||
Amortization |
6,367 | 5,924 | 5,270 | 5,255 | 4,922 | |||||||||||||||
Income from operations |
126,345 | 132,857 | 122,755 | 104,979 | 76,769 | |||||||||||||||
Income from continuing operations (b) |
74,037 | 68,369 | 60,440 | 57,722 | 36,228 | |||||||||||||||
Net income (b) |
73,784 | 67,281 | 61,641 | 50,651 | 35,817 | |||||||||||||||
Earnings per share |
||||||||||||||||||||
Income from continuing operations |
$ | 3.30 | $ | 2.97 | $ | 2.46 | $ | 2.21 | $ | 1.42 | ||||||||||
Net income |
3.29 | 2.92 | 2.51 | 1.94 | 1.40 | |||||||||||||||
Average number of shares outstanding |
22,451 | 23,058 | 24,520 | 26,118 | 25,552 | |||||||||||||||
Diluted earnings per share |
||||||||||||||||||||
Income from continuing operations |
$ | 3.26 | $ | 2.93 | $ | 2.41 | $ | 2.16 | $ | 1.38 | ||||||||||
Net income |
3.24 | 2.88 | 2.46 | 1.90 | 1.36 | |||||||||||||||
Average number of shares outstanding |
22,742 | 23,374 | 25,077 | 26,669 | 26,299 | |||||||||||||||
Cash dividends per share |
$ | 0.36 | $ | 0.24 | $ | 0.24 | $ | 0.24 | $ | 0.24 | ||||||||||
Financial PositionYear-End |
||||||||||||||||||||
Cash and cash equivalents |
$ | 112,416 | $ | 3,628 | $ | 4,988 | $ | 29,274 | $ | 57,133 | ||||||||||
Working capital/(deficit) |
62,174 | (18,142 | ) | (13,427 | ) | (3,951 | ) | 35,355 | ||||||||||||
Current ratio |
1.46 | 0.88 | 0.91 | 0.98 | 1.21 | |||||||||||||||
Properties and equipment, at cost less
accumulated depreciation |
$ | 75,358 | $ | 76,962 | $ | 74,513 | $ | 70,140 | $ | 65,155 | ||||||||||
Total assets |
819,470 | 759,622 | 768,945 | 791,461 | 837,343 | |||||||||||||||
Long-term debt |
152,127 | 158,210 | 163,715 | 150,331 | 234,058 | |||||||||||||||
Stockholders equity |
477,162 | 396,831 | 395,800 | 421,361 | 384,175 | |||||||||||||||
Other StatisticsContinuing Operations |
||||||||||||||||||||
Capital expenditures |
$ | 21,496 | $ | 26,094 | $ | 26,640 | $ | 21,987 | $ | 25,734 | ||||||||||
Number of employees |
12,308 | 11,884 | 11,783 | 11,621 | 10,881 |
(a) | Continuing operations exclude VITAS of Arizona, discontinued in 2006, Service America, discontinued in 2004 and Patient Care discontinued in 2002 | |
(b) | The following amounts are included in income from continuing operations during the respective year (in thousands): |
2009 | 2008 | 2007 | 2006 | 2005 | ||||||||||||||||
After-tax benefit/(cost): |
||||||||||||||||||||
Stock option expense |
$ | (5,464 | ) | $ | (4,619 | ) | $ | (2,962 | ) | $ | (769 | ) | $ | (137 | ) | |||||
Noncash impact of change in accounting for convertible debt |
(3,988 | ) | (4,006 | ) | (2,335 | ) | ||||||||||||||
Long-term incentive compensation |
(3,134 | ) | | (4,427 | ) | | (3,434 | ) | ||||||||||||
Expenses associated with contested proxy solicitation |
(2,525 | ) | | | | | ||||||||||||||
Non-taxable income on certain investments held in deferred
compensation trusts |
1,211 | | | | | |||||||||||||||
Costs related to litigation settlements |
(534 | ) | | (1,168 | ) | (169 | ) | (10,757 | ) | |||||||||||
Income tax impact of nondeductible losses on investments
held in deferred compensation trusts |
(455 | ) | (3,062 | ) | (46 | ) | | | ||||||||||||
Expenses incurred in connection with the Office of Inspector
General investigation |
(363 | ) | (28 | ) | (141 | ) | (662 | ) | (397 | ) | ||||||||||
Gain/(loss) on extinguishment of debt |
| 2,934 | (8,778 | ) | (273 | ) | (2,523 | ) | ||||||||||||
Loss on impairment of transportation equipment |
| (1,714 | ) | | | | ||||||||||||||
Unreserved prior-years insurance claim |
| (358 | ) | | | | ||||||||||||||
Income tax credits or adjustments related to prior years |
| 322 | | 2,115 | 1,961 | |||||||||||||||
Gain on sale of property |
| | 724 | | | |||||||||||||||
Loss on impairment of investment |
| | | (918 | ) | | ||||||||||||||
Adjustment to casualty insurance related to prior periods
experience |
| | | | 1,014 | |||||||||||||||
Adjustment of transaction-related expenses of the VITAS
acquisition |
| | | | 959 | |||||||||||||||
Other |
| | 296 | 296 | | |||||||||||||||
Total |
$ | (15,252 | ) | $ | (10,531 | ) | $ | (18,837 | ) | $ | (380 | ) | $ | (13,314 | ) | |||||
34
Chemed Corporation and Subsidiary Companies
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATING STATEMENT OF INCOME
FOR THE YEAR ENDED DECEMBER 31, 2009
(in thousands)(unaudited)
CONSOLIDATING STATEMENT OF INCOME
FOR THE YEAR ENDED DECEMBER 31, 2009
(in thousands)(unaudited)
Chemed | ||||||||||||||||
VITAS | Roto-Rooter | Corporate | Consolidated | |||||||||||||
2009 |
||||||||||||||||
Service revenues and sales |
$ | 854,343 | $ | 335,893 | $ | | $ | 1,190,236 | ||||||||
Cost of services provided and goods sold |
653,212 | 181,362 | | 834,574 | ||||||||||||
Selling, general and administrative expenses |
71,643 | 95,073 | 30,710 | 197,426 | ||||||||||||
Depreciation |
13,269 | 8,068 | 198 | 21,535 | ||||||||||||
Amortization |
3,959 | 114 | 2,294 | 6,367 | ||||||||||||
Other operating expenses |
| | 3,989 | 3,989 | ||||||||||||
Total costs and expenses |
742,083 | 284,617 | 37,191 | 1,063,891 | ||||||||||||
Income/(loss) from operations |
112,260 | 51,276 | (37,191 | ) | 126,345 | |||||||||||
Interest expense |
(374 | ) | (186 | ) | (11,039 | ) | (11,599 | ) | ||||||||
Intercompany interest income/(expense) |
4,314 | 2,514 | (6,828 | ) | | |||||||||||
Other income/(expense)net |
(122 | ) | 135 | 5,861 | 5,874 | |||||||||||
Income/(loss) before income
taxes |
116,078 | 53,739 | (49,197 | ) | 120,620 | |||||||||||
Income taxes |
(43,921 | ) | (20,493 | ) | 17,831 | (46,583 | ) | |||||||||
Income/(loss) from continuing operations |
72,157 | 33,246 | (31,366 | ) | 74,037 | |||||||||||
Discontinued operations |
| | (253 | ) | (253 | ) | ||||||||||
Net income/(loss) |
$ | 72,157 | $ | 33,246 | $ | (31,619 | ) | $ | 73,784 | |||||||
(a) | The following amounts are included in income from continuing operations (in thousands): |
Chemed | ||||||||||||||||
VITAS | Roto-Rooter | Corporate | Consolidated | |||||||||||||
Pretax benefit/(cost): |
||||||||||||||||
Stock option expense |
$ | | $ | | $ | (8,639 | ) | $ | (8,639 | ) | ||||||
Noncash impact of change in accounting for convertible
debt |
| | (6,305 | ) | (6,305 | ) | ||||||||||
Long-term incentive compensation |
| | (5,007 | ) | (5,007 | ) | ||||||||||
Expenses associated with contested proxy solicitation |
| | (3,989 | ) | (3,989 | ) | ||||||||||
Non-taxable income on certain investments held in deferred
compensation trusts |
| | 1,211 | 1,211 | ||||||||||||
Costs related to litigation settlements |
| (882 | ) | | (882 | ) | ||||||||||
Expenses incurred in connection with the Office of
Inspector
General investigation |
(586 | ) | | | (586 | ) | ||||||||||
Gain/(loss) on extinguishment of debt |
| | | | ||||||||||||
Total |
$ | (586 | ) | $ | (882 | ) | $ | (22,729 | ) | $ | (24,197 | ) | ||||
VITAS | Roto-Rooter | Corporate | Consolidated | |||||||||||||
After-tax benefit/(cost): |
||||||||||||||||
Stock option expense |
$ | | $ | | $ | (5,464 | ) | $ | (5,464 | ) | ||||||
Noncash impact of change in accounting for convertible debt |
| | (3,988 | ) | (3,988 | ) | ||||||||||
Long-term incentive compensation |
| | (3,134 | ) | (3,134 | ) | ||||||||||
Expenses associated with contested proxy solicitation |
| | (2,525 | ) | (2,525 | ) | ||||||||||
Non-taxable income on certain investments held in deferred
compensation trusts |
| | 1,211 | 1,211 | ||||||||||||
Income tax impact of nondeductible losses on investments
held in deferred compensation trusts |
| | (455 | ) | (455 | ) | ||||||||||
Costs related to litigation settlements |
| (534 | ) | | (534 | ) | ||||||||||
Expenses incurred in connection with the Office of Inspector
General investigation |
(363 | ) | | | (363 | ) | ||||||||||
Gain/(loss) on extinguishment of debt |
| | | | ||||||||||||
Total |
$ | (363 | ) | $ | (534 | ) | $ | (14,355 | ) | $ | (15,252 | ) | ||||
35
Chemed Corporation and Subsidiary Companies
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATING STATEMENT OF INCOME
FOR THE YEAR ENDED DECEMBER 31, 2008
(in thousands)(unaudited)
CONSOLIDATING STATEMENT OF INCOME
FOR THE YEAR ENDED DECEMBER 31, 2008
(in thousands)(unaudited)
Chemed | ||||||||||||||||
VITAS | Roto-Rooter | Corporate | Consolidated | |||||||||||||
2008 |
||||||||||||||||
Service revenues and sales |
$ | 808,445 | $ | 340,496 | $ | | $ | 1,148,941 | ||||||||
Cost of services provided and goods sold |
625,177 | 185,370 | | 810,547 | ||||||||||||
Selling, general and administrative expenses |
67,750 | 95,971 | 11,612 | 175,333 | ||||||||||||
Depreciation |
13,000 | 8,294 | 287 | 21,581 | ||||||||||||
Amortization |
3,984 | 50 | 1,890 | 5,924 | ||||||||||||
Other operating expenses |
| | 2,699 | 2,699 | ||||||||||||
Total costs and expenses |
709,911 | 289,685 | 16,488 | 1,016,084 | ||||||||||||
Income/(loss) from operations |
98,534 | 50,811 | (16,488 | ) | 132,857 | |||||||||||
Interest expense |
(155 | ) | (246 | ) | (11,722 | ) | (12,123 | ) | ||||||||
Intercompany interest income/(expense) |
5,199 | 3,708 | (8,907 | ) | | |||||||||||
Gain on extinguishment of debt |
| | 3,406 | 3,406 | ||||||||||||
Other income/(expense)net |
(149 | ) | 61 | (8,648 | ) | (8,736 | ) | |||||||||
Income/(loss) before income
taxes |
103,429 | 54,334 | (42,359 | ) | 115,404 | |||||||||||
Income taxes |
(38,710 | ) | (20,742 | ) | 12,417 | (47,035 | ) | |||||||||
Income/(loss) from continuing operations |
64,719 | 33,592 | (29,942 | ) | 68,369 | |||||||||||
Discontinued operations |
| | (1,088 | ) | (1,088 | ) | ||||||||||
Net income/(loss) |
$ | 64,719 | $ | 33,592 | $ | (31,030 | ) | $ | 67,281 | |||||||
(a) | The following amounts are included in income from continuing operations (in thousands): |
Chemed | ||||||||||||||||
VITAS | Roto-Rooter | Corporate | Consolidated | |||||||||||||
Pretax benefit/(cost): |
||||||||||||||||
Stock option expense |
$ | | $ | | $ | (7,303 | ) | $ | (7,303 | ) | ||||||
Noncash impact of change in accounting for
convertible debt |
| | (6,139 | ) | (6,139 | ) | ||||||||||
Impairment loss on transportation equipment |
| | (2,699 | ) | (2,699 | ) | ||||||||||
Gain on extinguishment of debt |
| | 3,406 | 3,406 | ||||||||||||
Unreserved prior-years insurance claim |
| (597 | ) | | (597 | ) | ||||||||||
Expenses incurred in connection with the Office
of Inspector
General investigation |
(46 | ) | | | (46 | ) | ||||||||||
Total |
$ | (46 | ) | $ | (597 | ) | $ | (12,735 | ) | $ | (13,378 | ) | ||||
VITAS | Roto-Rooter | Corporate | Consolidated | |||||||||||||
After-tax benefit/(cost): |
||||||||||||||||
Stock option expense |
$ | | $ | | $ | (4,619 | ) | $ | (4,619 | ) | ||||||
Noncash impact of change in accounting for convertible debt |
| | (4,006 | ) | (4,006 | ) | ||||||||||
Impairment loss on transportation equipment |
| | (1,714 | ) | (1,714 | ) | ||||||||||
Gain on extinguishment of debt |
| | 2,934 | 2,934 | ||||||||||||
Income tax impact of non-deductible net market losses
on investments held in deferred compensation trusts |
| | (3,062 | ) | (3,062 | ) | ||||||||||
Unreserved prior-years insurance claim |
| (358 | ) | | (358 | ) | ||||||||||
Expenses incurred in connection with the Office of Inspector
General investigation |
(28 | ) | | | (28 | ) | ||||||||||
Income tax credit related to prior years |
322 | | | 322 | ||||||||||||
Total |
$ | 294 | $ | (358 | ) | $ | (10,467 | ) | $ | (10,531 | ) | |||||
36
Chemed Corporation and Subsidiary Companies
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATING STATEMENT OF INCOME
FOR THE YEAR ENDED DECEMBER 31, 2007
(in thousands)(unaudited)
CONSOLIDATING STATEMENT OF INCOME
FOR THE YEAR ENDED DECEMBER 31, 2007
(in thousands)(unaudited)
Chemed | ||||||||||||||||
VITAS | Roto-Rooter | Corporate | Consolidated | |||||||||||||
2007 |
||||||||||||||||
Service revenues and sales |
$ | 755,426 | $ | 344,632 | $ | | $ | 1,100,058 | ||||||||
Cost of services provided and goods sold |
586,435 | 180,631 | | 767,066 | ||||||||||||
Selling, general and administrative expenses |
65,103 | 95,424 | 23,533 | 184,060 | ||||||||||||
Depreciation |
11,446 | 8,365 | 307 | 20,118 | ||||||||||||
Amortization |
3,984 | 54 | 1,232 | 5,270 | ||||||||||||
Other operating expenses |
| 1,927 | (1,138 | ) | 789 | |||||||||||
Total costs and expenses |
666,968 | 286,401 | 23,934 | 977,303 | ||||||||||||
Income/(loss) from operations |
88,458 | 58,231 | (23,934 | ) | 122,755 | |||||||||||
Interest expense |
(146 | ) | (495 | ) | (14,280 | ) | (14,921 | ) | ||||||||
Intercompany interest income/(expense) |
7,254 | 4,993 | (12,247 | ) | | |||||||||||
Loss on extinguishment of debt |
| | (13,798 | ) | (13,798 | ) | ||||||||||
Other income/(expense)net |
(11 | ) | 387 | 3,749 | 4,125 | |||||||||||
Income/(loss) before income
taxes |
95,555 | 63,116 | (60,510 | ) | 98,161 | |||||||||||
Income taxes |
(35,722 | ) | (24,145 | ) | 22,146 | (37,721 | ) | |||||||||
Income/(loss) from continuing operations |
59,833 | 38,971 | (38,364 | ) | 60,440 | |||||||||||
Discontinued operations |
1,201 | | | 1,201 | ||||||||||||
Net income/(loss) |
$ | 61,034 | $ | 38,971 | $ | (38,364 | ) | $ | 61,641 | |||||||
(a) | The following amounts are included in income from continuing operations (in thousands): |
Chemed | ||||||||||||||||
VITAS | Roto-Rooter | Corporate | Consolidated | |||||||||||||
Pretax benefit/(cost): |
||||||||||||||||
Stock option expense |
$ | | $ | | $ | (4,665 | ) | $ | (4,665 | ) | ||||||
Long-term incentive compensation |
| | (7,067 | ) | (7,067 | ) | ||||||||||
Noncash impact of change in accounting for convertible debt |
| | (3,677 | ) | (3,677 | ) | ||||||||||
Gain on sale of property |
| | 1,138 | 1,138 | ||||||||||||
Loss on extinguishment of debt |
| | (13,798 | ) | (13,798 | ) | ||||||||||
Unreserved prior-years insurance claim |
| (1,927 | ) | | (1,927 | ) | ||||||||||
Expenses incurred in connection with the Office of Inspector
General investigation |
(227 | ) | | | (227 | ) | ||||||||||
Other |
| | 467 | 467 | ||||||||||||
Total |
$ | (227 | ) | $ | (1,927 | ) | $ | (27,602 | ) | $ | (29,756 | ) | ||||
After-tax benefit/(cost): |
||||||||||||||||
Stock option expense |
$ | | $ | | $ | (2,962 | ) | $ | (2,962 | ) | ||||||
Long-term incentive compensation |
| | (4,427 | ) | (4,427 | ) | ||||||||||
Noncash impact of change in accounting for convertible debt |
| | (2,335 | ) | (2,335 | ) | ||||||||||
Gain on sale of property |
| | 724 | 724 | ||||||||||||
Loss on extinguishment of debt |
| | (8,778 | ) | (8,778 | ) | ||||||||||
Income tax impact of non-deductible net market losses
on investments held in deferred compensation trusts |
| | (46 | ) | (46 | ) | ||||||||||
Unreserved prior-years insurance claim |
| (1,168 | ) | | (1,168 | ) | ||||||||||
Expenses incurred in connection with the Office of Inspector
General investigation |
(141 | ) | | | (141 | ) | ||||||||||
Other |
| | 296 | 296 | ||||||||||||
Total |
$ | (141 | ) | $ | (1,168 | ) | $ | (17,528 | ) | $ | (18,837 | ) | ||||
37
Chemed Corporation and Subsidiary Companies
MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
EXECUTIVE SUMMARY
We operate through our two wholly owned subsidiaries: VITAS Healthcare Corporation (VITAS)
and Roto-Rooter Group, Inc. (Roto-Rooter). VITAS focuses on hospice care that helps make
terminally ill patients final days as comfortable as possible. Through its team of doctors,
nurses, home health aides, social workers, clergy and volunteers, VITAS provides direct medical
services to patients, as well as spiritual and emotional counseling to both patients and their
families. Roto-Rooter is focused on providing plumbing and drain cleaning services to both
residential and commercial customers. Through its network of company-owned branches, independent
contractors and franchisees, Roto-Rooter offers plumbing and drain cleaning service to over 90% of
the U.S. population.
The following is a summary of the key operating results for the years ended December 31, 2009,
2008 and 2007 (in thousands except percentages and per share amounts):
2009 | 2008 | 2007 | ||||||||||
Consolidated service revenues and sales |
$ | 1,190,236 | $ | 1,148,941 | $ | 1,100,058 | ||||||
Consolidated income from continuing
operations |
$ | 74,037 | $ | 68,369 | $ | 60,440 | ||||||
Diluted EPS from continuing operations |
$ | 3.26 | $ | 2.93 | $ | 2.41 | ||||||
Adjusted EBITDA* |
$ | 177,050 | $ | 161,754 | $ | 161,846 | ||||||
Adjusted EBITDA as a percent of revenue |
14.9 | % | 14.1 | % | 14.7 | % |
* | See page 50 for reconciliation to GAAP measures |
2009 versus 2008
The increase in consolidated service revenues and sales from 2008 to 2009 was driven by a 5.7%
increase at VITAS offset by an approximate 1.4% decrease at Roto-Rooter. The increase at VITAS was
the result of an increase in average daily census (ADC) of 1%, Medicare price increases and an
increase due to changes in the mix of care. The decrease at Roto-Rooter was driven by a 7%
decrease in the job count offset by an approximate 6% price and mix shift increase. Consolidated
income from continuing operations and diluted EPS from continuing operations increased as a result
of higher service revenues and sales, which allowed us to further leverage our current cost
structure. Adjusted EBITDA increased 9.5% from 2008 to 2009 and Adjusted EBITDA as a percent of
revenue increased from 14.1% to 14.9%.
2008 versus 2007
The increase in consolidated service revenues and sales from 2007 to 2008 was driven by a 7%
increase at VITAS offset by a 1% decrease at Roto-Rooter. The increase at VITAS was the result of
an increase in average daily census (ADC) of 3%, the annual Medicare price increase and an
increase due to changes in the mix of care. The decrease at Roto-Rooter was driven by a 10%
decrease in the job count offset by a 9% increase due to price increases and job mix changes.
Consolidated income from continuing operations and diluted EPS from continuing operations increased
as a result of higher service revenues and sales, which allowed us to further leverage our current
cost structure. 2008 diluted EPS from continuing operations also benefited from share repurchases
during the year of $69.8 million. The 2007 results were negatively impacted by pretax losses of
$13.8 million ($8.8 million aftertax) related to our refinancing transactions. Adjusted EBITDA was
essentially flat in 2008 when compared to 2007. Adjusted EBITDA as a percent of revenue decreased
from 14.7% in 2007 to 14.1% in 2008.
EBITDA and Adjusted EBITDA are not measures derived in accordance with GAAP and exclude
components that are important to understanding our financial performance. We use Adjusted EBITDA
as a measure of earnings for our LTIP awards. We provide EBITDA and Adjusted EBITDA to help
readers evaluate our operating results, compare our operating performance with that of similar
companies that have different capital structures and help evaluate our ability to meet future debt
service, capital expenditure and working capital requirements. Our EBITDA and Adjusted EBITDA
should not be considered in isolation or as a substitute for comparable measures presented in
accordance with GAAP. A reconciliation of our net income to our Adjusted EBITDA is presented in
tables following the Recent Accounting Statements section.
Impact of Current Market Conditions
Due mainly to the condition of the U.S. economy, Roto-Rooter customer call volume in 2009 was
down approximately 12.3% from the prior year. This led to a lower job count and lower total
revenue at Roto-Rooter, as discussed above. For full-year 2010, we expect Roto-Rooter to achieve
revenue growth of 1.0% to 3.0%. This is a result of increased pricing of 3.0%, a favorable mix
shift to higher revenue jobs, offset by job count decline of 2.0% to 4.0%.
38
Chemed Corporation and Subsidiary Companies
We expect VITAS to achieve full-year revenue growth, prior to Medicare cap, of 5.0% to 6.0%.
Admissions are estimated to increase 2.0% to 4.0%. This revenue estimate includes the October 1,
2009, 1.3% increase in average hospice reimbursement rates. We also expect VITAS to have estimated
Medicare contractual billing limitations of $5.0 million.
LIQUIDITY AND CAPITAL RESOURCES
Significant factors affecting our cash flows during 2009 and financial position at December
31, 2009, include the following:
| Our continuing operations generated cash of $160.8 million; | ||
| On a net basis, we repaid approximately $22.9 million of long-term debt; | ||
| We repurchased our stock using cash of $4.2 million; | ||
| We spent $21.5 million on capital expenditures. |
The ratio of total debt to total capital was 24.2% at December 31, 2009, compared with 29.8%
at December 31, 2008. Our current ratio was 1.46 and 0.88 at December 31, 2009 and 2008,
respectively.
Collectively, the 2007 Facility and the Notes require us to meet certain restrictive financial
covenants, in addition to non-financial covenants, including maximum leverage ratios, minimum fixed
charge coverage and consolidated net worth ratios, limits on operating leases and minimum asset
value limits. We are in compliance with all financial and non-financial debt covenants as of
December 31, 2009 and we forecast to be in compliance through fiscal 2010. We have issued $28.8
million in standby letters of credit as of December 31, 2009, mainly for insurance purposes.
Issued letters of credit reduce our available credit under the revolving credit agreement. As of
December 31, 2009, we have approximately $146.2 million of unused lines of credit available and
eligible to be drawn down under our revolving credit facility, excluding the expansion feature. We
believe our cash flow from operating activities and our unused eligible lines of credit are
sufficient to fund our obligations and operate our business in the near term. We continually
evaluate cash utilization alternatives, including share repurchase, debt repurchase, acquisitions,
and increased dividends to determine the most beneficial use of available capital resources.
CASH FLOW
Our cash flows for 2009, 2008 and 2007 are summarized as follows (in millions):
For the Years Ended December 31, | ||||||||||||
2009 | 2008 | 2007 | ||||||||||
Net cash provided by operating activities |
$ | 160.8 | $ | 112.1 | $ | 99.6 | ||||||
Capital expenditures |
(21.5 | ) | (26.1 | ) | (26.6 | ) | ||||||
Operating cash excess after capital expenditures |
139.3 | 86.0 | 73.0 | |||||||||
Purchase of treasury stock |
(4.2 | ) | (69.8 | ) | (131.7 | ) | ||||||
Repayment of long-term debt |
(22.9 | ) | (18.7 | ) | (225.7 | ) | ||||||
Business combinations |
(1.9 | ) | (11.2 | ) | (1.1 | ) | ||||||
Net proceeds/(uses) from sale of discontinued operations |
(0.6 | ) | 8.8 | (5.4 | ) | |||||||
Proceeds from issuance of long-term debt, net of costs |
| 8.2 | 245.1 | |||||||||
Proceeds from conversion feature of debt, net of costs |
| | 53.2 | |||||||||
Dividends paid |
(8.2 | ) | (5.5 | ) | (5.9 | ) | ||||||
Proceeds from exercise of stock options |
0.5 | 0.3 | 2.5 | |||||||||
Purchase of note hedge |
| | (55.1 | ) | ||||||||
Proceeds from issuance of warrants |
| | 27.6 | |||||||||
Othernet |
6.8 | 0.5 | (0.8 | ) | ||||||||
(Decrease)/increase in cash and cash equivalents |
$ | 108.8 | $ | (1.4 | ) | $ | (24.3 | ) | ||||
COMMITMENTS AND CONTINGENCIES
In connection with the sale of DuBois Chemicals, Inc. (DuBois) in 1991, we provided
allowances and accruals relating to several long-term costs, including income tax matters, lease
commitments and environmental costs. Also, in
conjunction with the sales of The Omnia Group (Omnia) and National Sanitary Supply Company
in 1997 and the sale of Service America Network Inc. (Service America) in 2005, we provided
long-term allowances and accruals relating to costs of severance arrangements, lease commitments
and income tax matters. Additionally, we retain liability for casualty insurance claims for
Service America and Patient Care that were incurred prior to the disposal date. In connection with
the sale of VITAS Phoenix operation in November 2006, we have accrued an estimate of our total
exposure for the Medicare Cap through the date of sale. In the aggregate, we believe these
allowances and accruals are adequate as of December 31, 2009. Based on reviews of our
environmental-related liabilities under the DuBois sale agreement, we have estimated our
39
Chemed Corporation and Subsidiary Companies
remaining
liability to be $1.7 million. As of December 31, 2009, we are contingently liable for additional
cleanup and related costs up to a maximum of $14.9 million, for which we believe it is not probable
that we will have to make any payment towards. Thus, no provision has been recorded in accordance
with the applicable accounting guidance.
VITAS is party to a class action lawsuit filed in the Superior Court of California, Los
Angeles County, in September 2006 by Bernadette Santos, Keith Knoche and Joyce White (Santos).
This case alleges failure to pay overtime and failure to provide meal and rest periods to a
purported class of California admissions nurses, chaplains and sales representatives. The case
seeks payment of penalties, interest and Plaintiffs attorney fees. VITAS contests these
allegations. In December 2009, the trial court denied Plantiffs motion for class certification.
The lawsuit is in its early stages and we are unable to estimate our potential liability, if any,
with respect to these allegations.
In April 2005, the Office of Inspector General (OIG) for the Department of Health and Human
Services served VITAS with civil subpoenas relating to VITAS alleged failure to appropriately bill
Medicare and Medicaid for hospice services. As part of this investigation, the OIG selected
medical records for 320 past and current patients from VITAS three largest programs for review.
It also sought policies and procedures dating back to 1998 covering admissions, certifications,
recertifications and discharges. During the third quarter of 2005 and again in May 2006, the OIG
requested additional information from us. The Court dismissed a related qui tam complaint filed in
U.S. District Court for the Southern District of Florida with prejudice in July 2007. The
plaintiffs appealed this dismissal, which the Court of Appeals affirmed. The government continues
to investigate the complaints allegations. In March 2009, we received a letter from the
government reiterating the basis of their investigation.
In May 2009, VITAS received an administrative subpoena from the U.S. Department of Justice
requesting VITAS deliver to the OIG documents, patient records, and policy and procedure manuals
for headquarters and its Texas programs concerning hospice services provided for the period January
1, 2003 to the date of the letter. In August 2009, the OIG selected medical records for 59 past
and current patients from a Texas program for review. In February 2010, VITAS received a companion
civil investigative demand from the state of Texas Attorney Generals office, seeking related
documents. Based on the early stage of the investigation and the limited information we have at
this time, we cannot predict the outcome of this investigation. We believe that we are in material
compliance with Medicare and Medicaid rules and regulations applicable to hospice providers.
We are unable to predict the outcome of these matters or the impact, if any, that the
investigation may have on our business, results of operations, liquidity or capital resources.
Regardless of outcome, responding to the subpoenas can adversely affect us through defense costs,
diversion of our time and related publicity.
CONTRACTUAL OBLIGATIONS
The table below summarizes our debt and contractual obligations as of December 31, 2009 (in
thousands):
Less than | After | |||||||||||||||||||
Total | 1 year | 1-3 Years | 4 -5 Years | 5 Years | ||||||||||||||||
Long-term debt obligations |
$ | 152,127 | $ | | $ | | $ | 152,127 | $ | | ||||||||||
Interest obligation on long-term debt (a) |
15,335 | 3,505 | 7,011 | 4,819 | | |||||||||||||||
Operating lease obligations |
53,393 | 16,579 | 21,947 | 11,198 | 3,669 | |||||||||||||||
Liabilities related to uncertain tax
positions |
1,010 | 373 | 363 | 244 | 30 | |||||||||||||||
Obligations of discontinued operations |
2,175 | 1,043 | 450 | 300 | 382 | |||||||||||||||
Purchase obligations (b) |
52,071 | 52,071 | | | | |||||||||||||||
Other current obligations (c ) |
34,662 | 34,662 | | | | |||||||||||||||
Other long-term obligations (d) |
26,403 | | 1,383 | 1,383 | 23,637 | |||||||||||||||
Total contractual cash obligations |
$ | 337,176 | $ | 108,233 | $ | 31,154 | $ | 170,071 | $ | 27,718 | ||||||||||
(a) | Our interest obligation on our long-term debt includes only interest on fixed rate debt. | |
(b) | Purchase obligations primarily consist of accounts payable at December 31, 2009. | |
(c) | Other current obligations consist of accrued salaries and wages at December 31, 2009. | |
(d) | Other long-term obligations comprise largely pension and excess benefit obligations. |
40
Chemed Corporation and Subsidiary Companies
RESULTS OF OPERATIONS
2009 Versus 2008 Consolidated Results
Set forth below are the year-to-year changes in the components of the statement of operations
relating to continuing operations for 2009 versus 2008 (in thousands, except percentages):
Favorable/(Unfavorable) | ||||||||
Amount | Percent | |||||||
Service revenues and sales |
||||||||
VITAS |
$ | 45,898 | 6 | |||||
Roto-Rooter |
(4,603 | ) | (2 | ) | ||||
Total |
41,295 | 4 | ||||||
Cost of services provided and goods sold |
(24,027 | ) | (3 | ) | ||||
Selling, general and administrative expenses |
(22,093 | ) | (13 | ) | ||||
Depreciation |
46 | | ||||||
Amortization |
(443 | ) | (7 | ) | ||||
Other expenses |
(1,290 | ) | (48 | ) | ||||
Income from operations |
(6,512 | ) | (5 | ) | ||||
Interest expense |
524 | 4 | ||||||
Gain on extinguishment of debt |
(3,406 | ) | (100 | ) | ||||
Other income net |
14,610 | 167 | ||||||
Income before income taxes |
5,216 | 5 | ||||||
Income taxes |
452 | 1 | ||||||
Income from continuing operations |
$ | 5,668 | 8 | |||||
Our service revenues and sales for the year ended December 31, 2009 increased $41.3
million or 3.6% over the comparable prior year. The VITAS segment accounted for $45.9 million of
the increase offset by a $4.6 million revenue decrease for the Roto-Rooter segment.
The VITAS segment revenue increase is the result of the following (dollars in thousands):
Amount | Percent | |||||||
Routine homecare |
$ | 29,517 | 5 | |||||
Continuous care |
16,378 | 13 | ||||||
General inpatient |
(539 | ) | (1 | ) | ||||
Estimated BNAF |
1,950 | | ||||||
Medicare cap allowance |
(1,408 | ) | 599 | |||||
Total revenues |
$ | 45,898 | 6 | |||||
The revenue increase for VITAS includes increases in the Medicare reimbursement rate of
approximately 3.5% as well as a $1.95 million increase for the BNAF, recorded in the first quarter
of 2009 but related to hospice care provided in the fourth quarter of 2008. In addition, the ADC
for routine homecare and continuous care increased 0.9% and 7.4%, respectively, from 2008. ADC for
general inpatient decreased 2.6% from 2008 to 2009. ADC is a key measure we use to monitor volume
growth in our hospice programs. Changes in total program admissions, discharges and average length
of stay for our patients are the main drivers of changes in ADC. The Medicare cap amount recorded
in 2009 relates predominantly to one programs liability through year end for the 2010 measurement
period. We are currently pursuing corrective actions to attempt to mitigate the liability before
the end of the measurement period. The 2008 revenue reduction for Medicare cap relates to one
programs liability through year end for the 2009 measurement period. This amount was subsequently
reversed during the 2009 fiscal year due to improved admission trends.
The Roto-Rooter segment revenue decrease is the result of the following (dollars in
thousands):
Amount | Percent | |||||||
Plumbing |
$ | 5,241 | 4 | |||||
Sewer and drain cleaning |
(9,647 | ) | (7 | ) | ||||
Other |
(197 | ) | | |||||
Total revenues |
$ | (4,603 | ) | (1 | ) | |||
41
Chemed Corporation and Subsidiary Companies
Plumbing revenues for 2009 increased from 2008 due to a 13% increase in the average price
per job offset by an 8% decrease in the number of jobs performed. The increase in the plumbing
price per job was driven mainly by job mix. Our excavation job count increased by 13% compared to
2008. The average revenue per excavation job is approximately 5 times greater than other average
plumbing jobs. Sewer and drain cleaning revenues for 2009 decreased from 2008 due to a 7% decrease
in jobs performed partially offset by a 1% increase in the average price per job. Other revenue
types are essentially flat when compared with 2008.
The consolidated gross margin was 29.9% in 2009 versus 29.5% in 2008. On a segment basis,
VITAS gross margin was 23.5% in 2009 and 22.7% in 2008. Roto-Rooters gross margin was 46.0% in
2009 and 45.6% in 2008. The increase in VITAS gross margin is a result of the $1.95 million BNAF
adjustment related to the fourth quarter of 2008 and refinements to scheduled field labor, offset
by an increase to Medicare cap liability of $1.4 million. Roto-Rooters gross margin increased
primarily as a result of favorable technician turnover rates and lower health insurance expense.
Selling, general and administrative expenses (SG&A) for 2009 increased $22.1 million (13%).
Included in SG&A is a $13.1 million increase related to the increase in our deferred compensation
liability due to improved stock market performance. The offset to the increased liability is
recorded in other (non-operating) income and expense. Also included in the SG&A increase is a 2009
LTIP award of $5.0 million, an increase of $1.3 million in stock option expense, an increase in OIG
expense of $540,000 and $882,000 related to litigation settlements. The remaining change in SG&A
is the result of typical cost of living increases for salaries and benefits plus increases in
certain selling expenses which vary based on changes in revenue.
Other operating expenses for 2009 of $4.0 million are related to the expenses of a contested
proxy solicitation. The $2.7 million of operating expense for 2008 relates to an impairment
charge on an eight passenger Hawker jet built in 1979. In December 2008, the Executive Committee
of the Board of Directors authorized us to place the 29 year-old Hawker for sale. We determined
that this asset met the definition of held for sale under FASBs guidance. As a result, we
discontinued depreciation on the jet and wrote-down the asset to its fair value less
selling costs resulting in a pre-tax charge to other operating expenses net of approximately
$2.7 million. In March 2009, we sold the jet and recognized an $112,000 gain on disposal.
Interest expense decreased $524,000 (4%) from 2008 to 2009 mainly due to repayment in 2008 of
$13.0 million face value of our Convertible Notes due May 2014 and repayment of remaining term loan
in 2009.
Other income/ (expense) net was $5.9 million income in 2009 compared to an $8.7 million
expense in 2008. The change is primarily the result of a $14.9 million gain from investments held
in deferred compensation plans due to market conditions.
Our effective tax rate was 38.6% in 2009 compared to 40.8% in 2008. The decrease in the
effective income tax rate is due primarily due to the impact of non-taxable gains and
non-deductible losses on investments in our deferred compensation benefit trusts.
In December 2009, we recorded a $400,000 pre-tax charge for retrospective casualty insurance
claims related to our discontinued operations. In 2008, the amount recorded for retrospective
casualty insurance claims related to discontinued operations was a $1.7 million pre-tax charge.
42
Chemed Corporation and Subsidiary Companies
Income from continuing operations for both periods include the following aftertax adjustments
that increased/ (reduced) aftertax earnings (in thousands):
2009 | 2008 | |||||||
VITAS |
||||||||
Costs associated with the OIG investigation |
$ | (363 | ) | $ | (28 | ) | ||
Tax adjustments required upon expiration of statutes |
| 322 | ||||||
Roto-Rooter |
||||||||
Costs related to litigation settlements |
(534 | ) | | |||||
Unreserved prior years insurance claims |
| (358 | ) | |||||
Corporate |
||||||||
Stock option expense |
(5,464 | ) | (4,619 | ) | ||||
Noncash impact of change in accounting of convertible debt |
(3,988 | ) | (4,006 | ) | ||||
Long-term incentive compensation |
(3,134 | ) | | |||||
Expenses associated with contested proxy solicitation |
(2,525 | ) | | |||||
Impact of non-deductible losses and non-taxable gains on
investments held in deferred compensation trusts |
756 | (3,062 | ) | |||||
Gain on extinguishment of debt |
| 2,934 | ||||||
Impairment of transportation equipment |
| (1,714 | ) | |||||
Total |
$ | (15,252 | ) | $ | (10,531 | ) | ||
2009 Versus 2008 Segment Results
The change in net income for 2009 versus 2008 is due to (in thousands, except percentages):
Increase/(Decrease) | ||||||||
Amount | Percent | |||||||
VITAS |
$ | 7,438 | 11 | |||||
Roto-Rooter |
(346 | ) | (1 | ) | ||||
Corporate |
(1,424 | ) | (5 | ) | ||||
Discontinued operations |
835 | 77 | ||||||
Total |
$ | 6,503 | 10 | |||||
2008 Versus 2007 Consolidated Results
Set forth below are the year-to-year changes in the components of the statement of operations
relating to continuing operations for 2008 versus 2007 (in thousands, except percentages):
Favorable/(Unfavorable) | ||||||||
Amount | Percent | |||||||
Service revenues and sales |
||||||||
VITAS |
$ | 53,019 | 7 | |||||
Roto-Rooter |
(4,136 | ) | (1 | ) | ||||
Total |
48,883 | 4 | ||||||
Cost of services provided and goods sold |
(43,481 | ) | (6 | ) | ||||
Selling, general and administrative expenses |
8,727 | 5 | ||||||
Depreciation |
(1,463 | ) | (7 | ) | ||||
Amortization |
(654 | ) | (12 | ) | ||||
Other expenses |
(1,910 | ) | (242 | ) | ||||
Income from operations |
10,102 | 8 | ||||||
Interest expense |
2,798 | 19 | ||||||
Loss on extinguishment of debt |
17,204 | 125 | ||||||
Other income net |
(12,861 | ) | (312 | ) | ||||
Income before income taxes |
17,243 | 18 | ||||||
Income taxes |
(9,314 | ) | (25 | ) | ||||
Income from continuing operations |
$ | 7,929 | 13 | |||||
43
Chemed Corporation and Subsidiary Companies
Our service revenues and sales for the year ended December 31, 2008 increased $48.9
million or 4.4% over the comparable prior year. The VITAS segment accounted for $53.0 million of
the increase offset by a $4.1 million revenue decrease for the Roto-Rooter segment.
The VITAS segment revenue increase is the result of the following (dollars in thousands):
Amount | Percent | |||||||
Routine homecare |
$ | 39,019 | 7 | |||||
Continuous care |
9,093 | 8 | ||||||
General inpatient |
4,900 | 5 | ||||||
Medicare cap |
7 | (3 | ) | |||||
Total revenues |
$ | 53,019 | 7 | |||||
The revenue increase for VITAS includes the annual increase in the Medicare
reimbursement rate of approximately 3% to 4% in fiscal 2007 and 2% to 3% in fiscal 2008. In
addition, the ADC for routine homecare and continuous care increased 3.4% and 2.1%, respectively,
from 2007. ADC for general inpatient was flat between years. ADC is a key measure we use to
monitor volume growth in our hospice programs. Changes in total program admissions and average
length of stay for our patients are the main drivers of changes in ADC. The Medicare cap amount
recorded in 2008 relates to one programs projected liability through year end for the 2009
measurement period. We are currently pursuing corrective actions to attempt to mitigate the
liability before the end of the measurement period. The 2007 revenue reduction for Medicare cap is
related to retroactive billings from prior periods for patients who transferred between hospice
providers.
The Roto-Rooter segment revenue decrease is the result of the following (dollars in
thousands):
Amount | Percent | |||||||
Plumbing |
$ | 2,810 | 2 | |||||
Sewer and drain cleaning |
(4,961 | ) | (3 | ) | ||||
Other |
(1,985 | ) | (4 | ) | ||||
Total revenues |
$ | (4,136 | ) | (1 | ) | |||
Plumbing revenues for 2008 increased from 2007 due to an 11% increase in the average
price per job offset by a 9% decrease in the number of jobs performed. The increase in the
plumbing price per job was driven mainly by job mix. Our excavation job count increased by 22%
compared to 2007. The average revenue per excavation job is approximately 4.5 times greater than
other average plumbing jobs. Sewer and drain cleaning revenues for 2008 decreased from 2007 due to
an 11% decrease in jobs performed partially offset by an 8% increase in the average price per job.
The decrease in other revenues is attributable primarily to decreased franchise fees and sales of
drain cleaning products and equipment.
The consolidated gross margin was 29.4% in 2008 versus 30.3% in 2007. On a segment basis,
VITAS gross margin was 22.7% in 2008 and 22.4% in 2007. Roto-Rooters gross margin was 45.6% in
2008 and 47.6% in 2007. The decrease in Roto-Rooters gross margin in 2008 is primarily
attributable to an increase in large medical claims affecting our health insurance costs.
Selling, general and administrative expenses (SG&A) for 2008 decreased $8.7 million (5%).
The decrease is mainly attributable to a 2007 LTIP award of $7.1 million. No LTIP awards were made
in 2008. Additionally, our liability related to the deferred compensation plans decreased by
approximately $8.4 million due to market performance. The offset to the decreased liability is
recorded in other (non-operating) income and expense. The remaining change in SG&A is the result
of typical cost of living increases for salaries and benefits plus increases in certain selling
expenses which vary based on changes in revenue.
The increase in other operating expenses relates to an impairment charge on a 29 year-old,
eight passenger Hawker jet. In December 2008, the Executive Committee of the Board of Directors
authorized us to place the 1979 Hawker for sale. We determined that
this asset met the
definition of held for sale per FASBs authoritative guidance. As a result, we discontinued
depreciation on the jet and wrote-down the asset to its fair value less selling costs
resulting in a pre-tax charge to other operating expenses net of approximately $2.7 million.
Interest expense decreased $2.8 million (19%) from 2007 to 2008 mainly due to the refinancing
in May 2007 and the subsequent repayment of long-term debt. In the fourth quarter of 2008, we
purchased approximately $13.0 million face value of our Convertible Notes due 2014 for
approximately $8.5 million. This resulted in a pre-tax net gain of $3.4 million
44
Chemed Corporation and Subsidiary Companies
comprised of $3.7
million related to the purchase of the Convertible Notes partially offset by $300,000 in the
write-off of unamortized debt issuance costs. The net gain was recorded as a gain on
extinguishment of debt in the accompanying statement of income in 2008. In conjunction with our
May 2007 refinancing transactions, we recorded a loss on extinguishment of debt of $13.8 million.
Other income/ (expense) net was an $8.7 million expense in 2008 compared to $4.1 million in
income in 2007. The change is the result of a $9.1 million loss from investments held in deferred
compensation plans due to market conditions, as well as a decrease of approximately $2.6 million in
interest income due to lower cash balances and reduced market interest rates.
Our effective tax rate was 40.8% in 2008 compared to 38.4% in 2007. The increase in the
effective income tax rate is due primarily to the impact of non-deductible market losses on
investments in our deferred compensation benefit trusts.
In December 2008, we recorded a $1.7 million pre-tax charge for retrospective casualty
insurance claims related to our discontinued operations. We have recorded the reversal of a $1.9
million over accrual and its related tax effects in discontinued operations during the year ended
December 31, 2007 related to Medicare cap at our discontinued Phoenix program.
Income from continuing operations for both periods include the following aftertax adjustments
that increased/ (reduced) aftertax earnings (in thousands):
2008 | 2007 | |||||||
VITAS |
||||||||
Costs associated with the OIG investigation |
$ | (28 | ) | $ | (141 | ) | ||
Tax adjustments required upon expiration of statutes |
322 | | ||||||
Roto-Rooter |
||||||||
Costs related to litigation settlements |
| (1,168 | ) | |||||
Unreserved prior years insurance claims |
(358 | ) | | |||||
Corporate |
||||||||
Stock option expense |
(4,619 | ) | (2,962 | ) | ||||
Noncash impact of change in accounting of convertible debt |
(4,006 | ) | (2,335 | ) | ||||
Impact of non-deductible losses and non-taxable gains on
investments held in deferred compensation trusts |
(3,062 | ) | (46 | ) | ||||
Gain on extinguishment of debt |
2,934 | (8,778 | ) | |||||
Impairment of transportation equipment |
(1,714 | ) | | |||||
Long-term incentive compensation |
| (4,427 | ) | |||||
Gain on sale of property |
| 724 | ||||||
Other |
| 296 | ||||||
Total |
$ | (10,531 | ) | $ | (18,837 | ) | ||
2008 Versus 2007 Segment Results
The change in net income for 2008 versus 2007 is due to (in thousands, except percentages):
Increase/(Decrease) | ||||||||
Amount | Percent | |||||||
VITAS |
$ | 4,886 | 8 | |||||
Roto-Rooter |
(5,379 | ) | (14 | ) | ||||
Corporate |
8,422 | (22 | ) | |||||
Discontinued operations |
(2,289 | ) | (191 | ) | ||||
Total |
$ | 5,640 | 9 | |||||
45
Chemed Corporation and Subsidiary Companies
CRITICAL ACCOUNTING POLICIES
Revenue Recognition
For both the Roto-Rooter and VITAS segments, service revenues and sales are recognized when
the earnings process has been completed. Generally, this occurs when services are provided or
products are delivered. Sales of Roto-Rooter products, including drain cleaning machines and drain
cleaning solution, comprise less than 3% of our total service revenues and sales for each of the
three years in the period ended December 31, 2009.
VITAS recognizes revenue at the estimated net realizable amount due from third-party payers,
which are primarily Medicare and Medicaid. Payers may deny payment for services in whole or in
part on the basis that such services are not eligible for coverage and do not qualify for
reimbursement. We estimate denials each period and make adequate provision in the financial
statements. The estimate of denials is based on historical trends and known circumstances and
generally does not vary materially from period to period on an aggregate basis. Medicare billings
are subject to certain limitations, as described below.
VITAS is subject to certain limitations on Medicare payments for services. Specifically, if
the number of inpatient care days any hospice program provides to Medicare beneficiaries exceeds
20% of the total days of Medicare hospice care such program provides to all patients for an annual
period beginning September 28, the days in excess of the 20% figure may be reimbursed only at the
routine homecare rate. We have never had a program reach the inpatient cap. None of our hospice
programs are expected to be within 30% of the inpatient cap for the 2009 measurement period while
the majority of our programs have expected cushion in excess of 75% of the inpatient cap. Due to
the significant cushion at each program, we do not anticipate it to be reasonably likely that any
program will be subject to the inpatient cap in the foreseeable future.
VITAS is also subject to a Medicare annual per-beneficiary cap. Compliance with the Medicare
cap is measured by comparing the total Medicare payments received under a Medicare provider number
with respect to services provided to all Medicare hospice care beneficiaries in the program or
programs covered by that Medicare provider number between November 1 of each year and October 31 of
the following year with the product of the per-beneficiary cap amount and the number of Medicare
beneficiaries electing hospice care for the first time from that hospice program or programs during
the relevant period.
We actively monitor each of our hospice programs, by provider number, as to their specific
admissions, discharge rate and median length of stay data in an attempt to determine whether they
are likely to exceed the Medicare cap. Should we determine that a provider number is likely to
exceed the Medicare cap based on projected trends, we attempt to institute corrective action to
influence the patient mix or to increase patient admissions. However, should we project our
corrective action will not prevent that program from exceeding its Medicare cap, we estimate the
amount of revenue recognized during the period that will require repayment to the Federal
government under the Medicare cap and record that amount as a reduction in service revenue.
Our estimate of the Medicare cap liability is particularly sensitive to allocations made by
our fiscal intermediary relative to patient transfers between hospices. We are allocated a
percentage of the Medicare cap based on the total days a patient spent in hospice care. The
allocation for patient transfers cannot be determined until a patient dies. As the number of days
a patient spends in hospice is based on a future event, this allocation process may take several
years. Therefore, we use only first time Medicare admissions in our estimate of the Medicare cap
billing limitation. This method assumes that credit received for patients who transfer into our
program will be offset by credit lost from patients who transfer out of our program. If the actual
relationship of transfers in and transfers out for a given measurement period proves to be
different for any program at or near a billing limitation, our estimate of the liability would
increase or decrease on a dollar-for-dollar basis. While our method has historically been
materially accurate, each program can vary during a given measurement period.
During the years ended December 31, 2009, 2008 and 2007, we recorded pretax charges in
continuing operations of $1.6 million, $235,000 and $242,000, respectively, for the estimated
Medicare cap liability. The amount recorded in 2009 relates to two programs liability through
year end for the 2010 measurement period. We are currently pursuing the corrective actions
mentioned above to attempt to mitigate the liability before the end of the measurement period. The
amount
recorded in 2008 relates to one programs projected liability through year end for the 2009
measurement period. This amount was subsequently reversed during the 2009 fiscal year due to
improved admission trends. The amount recorded in 2007 relates primarily to retroactive billings
for prior-measurement periods due to patients who transferred between multiple hospice providers.
46
Chemed Corporation and Subsidiary Companies
The components of the pretax charge in 2009 are as follows (in thousands):
2010 Measurement period |
$ | 1,783 | ||
2009 Measurement period |
(235 | ) | ||
2008 Measurement period |
| |||
Retroactive billings |
95 | |||
Total |
$ | 1,643 | ||
The U.S. government revises hospice reimbursement rates on an annual basis using the Hospice
Wage Index (HWI) and Consumer Price Index (CPI) plus a phase out of the Budget Neutrality
Adjustment Factor (BNAF). The HWI is geographically adjusted to reflect local differences in
wages. The BNAF is a portion of inflation calculated in prior years that is being eliminated or
phased out over a seven year period. In August 2008, the U.S. government announced a 25% reduction
in the BNAF for its fiscal 2009 (October 2008 through September 2009) pursuant to a three year
phase-out of the BNAF. The February 2009 American Recovery and Reinvestment Act mandated a one
year delay in the BNAF phase-out. In August 2009, the Centers for Medicare and Medicaid Services
(CMS) revised the phase-out schedule of the BNAF. CMS reduced the increase in hospice
reimbursement by 10% of the BNAF effective October 1, 2009. The remaining 90% of the BNAF will be
phased out over the next six years by revising the October 1 reimbursement adjustment by 15% of
the original BNAF inflation factor. Based upon this revised schedule, 100% of the BNAF will be
eliminated on October 1, 2015. As a result, included in the twelve months ended December 31, 2009
results, is $1.95 million of revenue for the retroactive price increase related to services
provided by VITAS in the fourth quarter of 2008.
Insurance Accruals
For the Roto-Rooter segment and Chemeds Corporate Office, we self-insure for all casualty
insurance claims (workers compensation, auto liability and general liability). As a result, we
closely monitor and frequently evaluate our historical claims experience to estimate the
appropriate level of accrual for self-insured claims. Our third-party administrator (TPA)
processes and reviews claims on a monthly basis. Currently, our exposure on any single claim is
capped at $500,000. In developing our estimates, we accumulate historical claims data for the
previous 10 years to calculate loss development factors (LDF) by insurance coverage type. LDFs
are applied to known claims to estimate the ultimate potential liability for known and unknown
claims for each open policy year. LDFs are updated annually. Because this methodology relies
heavily on historical claims data, the key risk is whether the historical claims are an accurate
predictor of future claims exposure. The risk also exists that certain claims have been incurred
and not reported on a timely basis. To mitigate these risks, in conjunction with our TPA, we
closely monitor claims to ensure timely accumulation of data and compare claims trends with the
industry experience of our TPA.
For the VITAS segment, we self-insure for workers compensation claims. Currently, VITAS
exposure on any single claim is capped at $750,000. For VITAS self-insurance accruals for
workers compensation, the valuation methods used are similar to those used internally for our
other business units.
Our casualty insurance liabilities are recorded gross before any estimated recovery for
amounts exceeding our stop loss limits. Estimated recoveries from insurance carriers are recorded
as accounts receivable. Claims experience adjustments to our casualty and workers compensation
accrual for the years ended December 31, 2009, 2008 and 2007 were net, pretax debits/(credits) of
$1.9 million, $52,000 and ($2.9 million), respectively.
As an indication of the sensitivity of the accrued liability to reported claims, our analysis
indicates that a 1% across-the-board increase or decrease in the amount of projected losses for all
of our continuing operations would increase or decrease the accrued insurance liability at December
31, 2009, by $1.7 million or 5.0%. While the amount recorded represents our best estimate of the
casualty and workers compensation insurance liability, we have calculated, based on
historical claims experience, the actual loss could reasonably be expected to increase or
decrease by approximately $2.6 million as of December 31, 2009.
Income Taxes
Deferred taxes are provided on an asset and liability method whereby deferred tax assets are
recognized for deductible temporary differences and operating loss carry-forwards and deferred tax
liabilities are recognized for taxable temporary differences. Temporary differences are the
differences between the reported amount of assets and liabilities and their tax basis. Deferred
tax assets are reduced by a valuation allowance when, in our opinion, it is more likely than not
that
47
Chemed Corporation and Subsidiary Companies
some portion or all of the deferred tax assets will not be realized. Deferred tax assets and
liabilities are adjusted for the effects of changes in laws and rates on the date of enactment.
We are subject to income taxes in the Federal and most state jurisdictions. We are
periodically audited by various taxing authorities. Significant judgment is required to determine
our provision for income taxes. On January 1, 2007, we adopted FASBs authoritative guidance on
accounting for uncertainty in income taxes, which prescribes a comprehensive model for how to
recognize, measure, present and disclose in financial statements uncertain tax positions taken or
expected to be taken on a tax return. Upon adoption of this guidance, the financial statements
reflect expected future tax consequences of such uncertain positions assuming the taxing
authorities full knowledge of the position and all relevant facts.
Goodwill and Intangible Assets
Identifiable, definite-lived intangible assets arise from purchase business combinations and
are amortized using either an accelerated method or the straight-line method over the estimated
useful lives of the assets. The selection of an amortization method is based on which method best
reflects the economic pattern of usage of the asset. The VITAS trade name is considered to have an
indefinite life. Goodwill and the VITAS trade name are tested at least annually for impairment.
The valuation of goodwill and the VITAS trade name is dependent upon many factors, some of which
are market-driven and beyond our control. The valuation of goodwill and the VITAS trade name
indicate no impairment. We have significant excess of estimated market value over our asset base
for each reporting unit tested at October 1, 2009 and do not expect that an impairment charge is
likely in the foreseeable future. However, we are unable to predict all factors that may impact
future impairment analysis.
Stock-based Compensation Plans
Stock-based compensation cost is measured at the grant date, based on the fair value of the
award and recognized as expense over the employees requisite service period on a straight-line
basis. We estimate the fair value of stock options using the Black-Scholes valuation model,
consistent with the guidance provided by the FASB and the SEC. We determine expected term,
volatility, dividend yield and forfeiture rate based on our historical experience. We believe that
historical experience is the best indicator of these factors.
RECENT ACCOUNTING STATEMENTS
In June 2009, the FASB issued additional guidance related to the consolidation of variable
interest entities, which makes significant changes to the model for determining who should
consolidate an entity and also addresses how often this assessment should be performed. The
determination of who should consolidate a variable interest entity will be based on both
quantitative and qualitative factors relating to control, as well as risks and benefits of
ownership. This guidance is effective in 2010 for calendar-year companies and is to be adopted
through a cumulative-effect adjustment. Based on our analysis, we believe that neither
Roto-Rooters independent contractors nor franchisees qualify as VIEs under the new guidance.
48
Chemed Corporation and Subsidiary Companies
Consolidating Summary of Adjusted EBITDA
Chemed Corporation and Subsidiary Companies
(in thousands)
(in thousands)
Chemed | ||||||||||||||||
2009 | VITAS | Roto-Rooter | Corporate | Consolidated | ||||||||||||
Net income/(loss) |
$ | 72,157 | $ | 33,246 | $ | (31,619 | ) | $ | 73,784 | |||||||
Add/(deduct): |
||||||||||||||||
Discontinued operations |
| | 253 | 253 | ||||||||||||
Interest expense |
374 | 186 | 11,039 | 11,599 | ||||||||||||
Income taxes |
43,921 | 20,493 | (17,831 | ) | 46,583 | |||||||||||
Depreciation |
13,269 | 8,068 | 198 | 21,535 | ||||||||||||
Amortization |
3,959 | 114 | 2,294 | 6,367 | ||||||||||||
EBITDA |
133,680 | 62,107 | (35,666 | ) | 160,121 | |||||||||||
Add/(deduct): |
||||||||||||||||
Long-term incentive compensation |
| | 5,007 | 5,007 | ||||||||||||
Non-taxable income from certain investments
held in
deferred
compensation trusts |
| | (1,211 | ) | (1,211 | ) | ||||||||||
Litigation Settlement costs |
| 882 | | 882 | ||||||||||||
Expenses associated with contested proxy
solicitation |
| | 3,989 | 3,989 | ||||||||||||
Legal expenses of OIG investigation |
586 | | | 586 | ||||||||||||
Stock option expense |
| | 8,639 | 8,639 | ||||||||||||
Advertising cost adjustment |
| (540 | ) | | (540 | ) | ||||||||||
Interest income |
(267 | ) | (73 | ) | (83 | ) | (423 | ) | ||||||||
Intercompany interest/(expense) |
(4,314 | ) | (2,514 | ) | 6,828 | | ||||||||||
Adjusted EBITDA |
$ | 129,685 | $ | 59,862 | $ | (12,497 | ) | $ | 177,050 | |||||||
Chemed | ||||||||||||||||
2008 | VITAS | Roto-Rooter | Corporate | Consolidated | ||||||||||||
Net income/(loss) |
$ | 64,719 | $ | 33,592 | $ | (31,030 | ) | $ | 67,281 | |||||||
Add/(deduct): |
||||||||||||||||
Discontinued operations |
| | 1,088 | 1,088 | ||||||||||||
Interest expense |
155 | 246 | 11,722 | 12,123 | ||||||||||||
Income taxes |
38,710 | 20,742 | (12,417 | ) | 47,035 | |||||||||||
Depreciation |
13,000 | 8,294 | 287 | 21,581 | ||||||||||||
Amortization |
3,984 | 50 | 1,890 | 5,924 | ||||||||||||
EBITDA |
120,568 | 62,924 | (28,460 | ) | 155,032 | |||||||||||
Add/(deduct): |
||||||||||||||||
Unreserved insurance claim |
| 597 | | 597 | ||||||||||||
Impairment loss on transportation
equipment |
| | 2,699 | 2,699 | ||||||||||||
Legal expenses of OIG investigation |
46 | | | 46 | ||||||||||||
Stock option expense |
| | 7,303 | 7,303 | ||||||||||||
Gain on extinguishment of debt |
| | (3,406 | ) | (3,406 | ) | ||||||||||
Advertising cost adjustment |
| 225 | | 225 | ||||||||||||
Interest income |
(137 | ) | (116 | ) | (489 | ) | (742 | ) | ||||||||
Intercompany interest/(expense) |
(5,199 | ) | (3,708 | ) | 8,907 | | ||||||||||
Adjusted EBITDA |
$ | 115,278 | $ | 59,922 | $ | (13,446 | ) | $ | 161,754 | |||||||
Chemed | ||||||||||||||||
2007 | VITAS | Roto-Rooter | Corporate | Consolidated | ||||||||||||
Net income/(loss) |
$ | 61,034 | $ | 38,971 | $ | (38,364 | ) | $ | 61,641 | |||||||
Add/(deduct): |
||||||||||||||||
Discontinued operations |
(1,201 | ) | | | (1,201 | ) | ||||||||||
Interest expense |
146 | 495 | 14,280 | 14,921 | ||||||||||||
Income taxes |
35,722 | 24,145 | (22,146 | ) | 37,721 | |||||||||||
Depreciation |
11,446 | 8,365 | 307 | 20,118 | ||||||||||||
Amortization |
3,984 | 54 | 1,232 | 5,270 | ||||||||||||
EBITDA |
111,131 | 72,030 | (44,691 | ) | 138,470 | |||||||||||
Add/(deduct): |
||||||||||||||||
Long-term incentive compensation |
| | 7,067 | 7,067 | ||||||||||||
Litigation settlement costs |
| 1,927 | | 1,927 | ||||||||||||
Gain on sale of property |
| | (1,138 | ) | (1,138 | ) | ||||||||||
Legal expenses of OIG investigation |
227 | | | 227 | ||||||||||||
Stock option expense |
| | 4,665 | 4,665 | ||||||||||||
Loss on extinguishment of debt |
| | 13,798 | 13,798 | ||||||||||||
Advertising cost adjustment |
| 601 | | 601 | ||||||||||||
Interest income |
(151 | ) | (377 | ) | (2,776 | ) | (3,304 | ) | ||||||||
Intercompany interest/(expense) |
(7,254 | ) | (4,993 | ) | 12,247 | | ||||||||||
Other |
| | (467 | ) | (467 | ) | ||||||||||
Adjusted EBITDA |
$ | 103,953 | $ | 69,188 | $ | (11,295 | ) | $ | 161,846 | |||||||
49
Chemed Corporation and Subsidiary Companies
RECONCILIATION OF NET INCOME TO ADJUSTED EBITDA
Chemed Corporation and Subsidiary Companies
(in thousands)
(in thousands)
For the Years Ended December 31, | 2009 | 2008 | 2007 | |||||||||
Net income/(loss) |
$ | 73,784 | $ | 67,281 | $ | 61,641 | ||||||
Add/(deduct): |
||||||||||||
Discontinued operations |
253 | 1,088 | (1,201 | ) | ||||||||
Interest expense |
11,599 | 12,123 | 14,921 | |||||||||
Income taxes |
46,583 | 47,035 | 37,721 | |||||||||
Depreciation |
21,535 | 21,581 | 20,118 | |||||||||
Amortization |
6,367 | 5,924 | 5,270 | |||||||||
EBITDA |
160,121 | 155,032 | 138,470 | |||||||||
Add/(deduct): |
||||||||||||
Long-term incentive compensation |
5,007 | | 7,067 | |||||||||
Non-taxable
income from certain investments held in deferred compensation
trusts |
(1,211 | ) | | | ||||||||
Litigation
Settlement costs |
882 | | 1,927 | |||||||||
Expenses associated with contested proxy
solicitation |
3,989 | | | |||||||||
Legal expenses of OIG investigation |
586 | 46 | 227 | |||||||||
Stock option expense |
8,639 | 7,303 | 4,665 | |||||||||
Advertising cost adjustment |
(540 | ) | 225 | 601 | ||||||||
Interest income |
(423 | ) | (742 | ) | (3,304 | ) | ||||||
(Gain)/loss on extinguishment of debt |
| (3,406 | ) | 13,798 | ||||||||
Gain on sale of property |
| | (1,138 | ) | ||||||||
Unreserved insurance claim |
| 597 | | |||||||||
Impairment loss on transportation equipment |
| 2,699 | | |||||||||
Other |
| | (467 | ) | ||||||||
Adjusted EBITDA |
$ | 177,050 | $ | 161,754 | $ | 161,846 | ||||||
50
Chemed Corporation and Subsidiary Companies
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
OPERATING STATISTICS FOR VITAS SEGMENT
(unaudited)
OPERATING STATISTICS FOR VITAS SEGMENT
(unaudited)
Three Months Ended December 31, | Year Ended December 31, | |||||||||||||||
OPERATING STATISTICS | 2009 | 2008 | 2009 | 2008 | ||||||||||||
Net revenue ($000) |
||||||||||||||||
Homecare |
$ | 159,248 | $ | 149,816 | $ | 615,408 | $ | 585,891 | ||||||||
Inpatient |
24,550 | 23,398 | 97,356 | 97,895 | ||||||||||||
Continuous care |
35,593 | 32,877 | 141,272 | 124,894 | ||||||||||||
Total before Medicare cap allowance and 2008 BNAF |
$ | 219,391 | $ | 206,091 | $ | 854,036 | $ | 808,680 | ||||||||
Estimated BNAF |
| | 1,950 | | ||||||||||||
Medicare cap allowance |
(1,835 | ) | (235 | ) | (1,643 | ) | (235 | ) | ||||||||
Total |
$ | 217,556 | $ | 205,856 | $ | 854,343 | $ | 808,445 | ||||||||
Net revenue as a percent of total
before Medicare cap allowance |
||||||||||||||||
Homecare |
72.6 | % | 72.6 | % | 72.1 | % | 72.5 | % | ||||||||
Inpatient |
11.2 | 11.4 | 11.4 | 12.1 | ||||||||||||
Continuous care |
16.2 | 16.0 | 16.5 | 15.4 | ||||||||||||
Total before Medicare cap allowance and 2008 BNAF |
100.0 | 100.0 | 100.0 | 100.0 | ||||||||||||
Estimated BNAF |
| | 0.2 | | ||||||||||||
Medicare cap allowance |
(0.8 | ) | (0.1 | ) | (0.2 | ) | | |||||||||
Total |
99.2 | % | 99.9 | % | 100.0 | % | 100.0 | % | ||||||||
Average daily census (days) |
||||||||||||||||
Homecare |
7,933 | 7,458 | 7,730 | 7,374 | ||||||||||||
Nursing home |
3,253 | 3,452 | 3,281 | 3,535 | ||||||||||||
Routine homecare |
11,186 | 10,910 | 11,011 | 10,909 | ||||||||||||
Inpatient |
407 | 386 | 406 | 417 | ||||||||||||
Continuous care |
556 | 533 | 563 | 524 | ||||||||||||
Total |
12,149 | 11,829 | 11,980 | 11,850 | ||||||||||||
Total Admissions |
13,677 | 13,314 | 55,420 | 55,799 | ||||||||||||
Total Discharges |
13,667 | 13,693 | 54,814 | 55,691 | ||||||||||||
Average length of stay (days) |
76.4 | 83.1 | 76.0 | 75.4 | ||||||||||||
Median length of stay (days) |
14.0 | 14.0 | 14.0 | 14.0 | ||||||||||||
ADC by major diagnosis |
||||||||||||||||
Neurological |
33.0 | % | 33.1 | % | 33.0 | % | 32.7 | % | ||||||||
Cancer |
18.8 | 19.3 | 19.1 | 19.8 | ||||||||||||
Cardio |
11.9 | 12.5 | 12.1 | 12.8 | ||||||||||||
Respiratory |
6.3 | 6.5 | 6.4 | 6.6 | ||||||||||||
Other |
30.0 | 28.6 | 29.4 | 28.1 | ||||||||||||
Total |
100.0 | % | 100.0 | % | 100.0 | % | 100.0 | % | ||||||||
Admissions by major diagnosis |
||||||||||||||||
Neurological |
18.8 | % | 18.6 | % | 18.1 | % | 18.4 | % | ||||||||
Cancer |
35.8 | 35.9 | 35.7 | 35.7 | ||||||||||||
Cardio |
10.4 | 11.1 | 11.5 | 11.6 | ||||||||||||
Respiratory |
7.5 | 7.6 | 7.5 | 7.8 | ||||||||||||
Other |
27.5 | 26.8 | 27.2 | 26.5 | ||||||||||||
Total |
100.0 | % | 100.0 | % | 100.0 | % | 100.0 | % | ||||||||
Direct patient care margins |
||||||||||||||||
Routine homecare |
52.5 | % | 53.3 | % | 52.0 | % | 51.2 | % | ||||||||
Inpatient |
11.6 | 14.9 | 14.6 | 17.2 | ||||||||||||
Continuous care |
20.1 | 20.1 | 20.2 | 18.1 | ||||||||||||
Homecare margin drivers (dollars per patient day) |
||||||||||||||||
Labor costs |
$ | 51.89 | $ | 48.99 | $ | 52.27 | $ | 49.87 | ||||||||
Drug costs |
7.58 | 7.87 | 7.63 | 7.74 | ||||||||||||
Home medical equipment |
6.91 | 6.32 | 6.86 | 6.24 | ||||||||||||
Medical supplies |
2.55 | 2.22 | 2.42 | 2.32 | ||||||||||||
Inpatient margin drivers (dollars per patient day) |
||||||||||||||||
Labor costs |
$ | 300.26 | $ | 266.86 | $ | 287.16 | $ | 264.45 | ||||||||
Continuous care margin drivers (dollars per patient day) |
||||||||||||||||
Labor costs |
$ | 534.60 | $ | 514.93 | $ | 527.27 | $ | 512.61 | ||||||||
Bad debt expense as a percent of revenues |
1.1 | % | 1.1 | % | 1.1 | % | 1.0 | % | ||||||||
Accounts receivable |
||||||||||||||||
Days of revenue outstanding- excluding unapplied Medicare payments |
48.3 | 49.1 | N.A. | N.A. | ||||||||||||
Days of revenue outstanding- including unapplied Medicare payments |
18.0 | 34.7 | N.A. | N.A. |
51
Chemed Corporation and Subsidiary Companies
SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 REGARDING
FORWARD-LOOKING INFORMATION
In addition to historical information, this report contains forward-looking statements and
performance trends that are based upon assumptions subject to certain known and unknown risks,
uncertainties, contingencies and other factors. Such forward-looking statements and trends include,
but are not limited to, the impact of laws and regulations on our operations, our estimate of
future effective income tax rates and the recoverability of deferred tax assets. Variances in any
or all of the risks, uncertainties, contingencies, and other factors from our assumptions could
cause actual results to differ materially from these forward-looking statements and trends. Our
ability to deal with the unknown outcomes of these events, many of which are beyond our control,
may affect the reliability of our projections and other financial matters.
52